Introduction {#Sec1}
============

As a transition metal that can exist in several valencies, and that can bind up to six ligands, iron is an important component of industrial catalysts in the chemical industry (Hagen [@CR581]), especially for redox reactions. Its catalysis of specific reactions requires rather exact architectures at the catalytic centre, and indeed much of the art and science of catalyst production involves determining and synthesising them. Nearly half of all enzymes are metalloproteins (Waldron et al. [@CR1578]), and iron is also of considerable importance in biology as a component of all kinds of metalloproteins (Andreini et al. [@CR53], [@CR54]) from haemoglobin to cytochromes, as well as in the directed evolution of*novel* enzyme activities (Pordea and Ward [@CR1214]; Que and Tolman [@CR1231]; Turner [@CR1533]). When serving in enzymes, the iron is normally safely liganded, and any reactions catalysed are usually fairly specific. However, as is widely recognised, iron can also have a dark side (Kell [@CR766]), in that when it is not properly liganded (Graf et al. [@CR550]), and in the ferrous form, it can react with hydrogen peroxide (produced by mitochondria (e.g. Brennan and Kantorow [@CR188]; Fato et al. [@CR415]; Orrenius et al. [@CR1138]) or (per)oxidases (Bedard and Krause [@CR127]; Cave et al. [@CR250]) via the Fenton reaction (Goldstein et al. [@CR523]; Kruszewski [@CR844]; Toyokuni [@CR1518]; Wardman and Candeias [@CR1597]; Winterbourn [@CR1635]), leading to the very reactive and damaging hydroxyl radical (OH^•^)Fig. 1The Haber-Weiss and Fenton reactions combine using poorly liganded iron in a **catalytic cycle** to produce the very damaging hydroxyl radical. Poorly liganded iron can also be liberated via the destruction of haem and other iron-containing substances. Peroxynitrite anion (ONOO^−^) is produced by the reaction of superoxide and nitric oxide (NO^•^) which when protonated (pH ca 6.5--6.8) decomposes to OH^•^ and NO~2~Fig. 2Some small molecules that are derived from the oxidative attack of hydroxyl and other radicals on cellular macromolecules and that can act as biomarkers of oxidative stress, including that mediated by ironFig. 3Very strong relationship between serum ferritin concentrations and urinary concentrations of the DNA damage/oxidative stress marker 8-hydroxy-2′-deoxyguanosine. Data are replotted from Fig. 1 of Hori et al. ([@CR643])Fig. 4A mind map (Buzan [@CR219]) setting out the structure of this review. To read this start at "1 o'clock" and move outwards and clockwiseFig. 5Some of the interactions between the prion protein in its two main conformations, reactive oxygen species and iron dysregulation. This diagram is based on Fig. 12 of (Singh et al. [@CR1394]), and illustrates in particular the autocatalytic nature of the ROS- and iron-dependent conversion of PrP^C^ to PrP^Sc^ and the neurotoxicity of the latterFig. 6Iron catalyses the formation of the hydroxyl radical (and thence other kinds of ROS) that can react with proteins and lipids to denature them, leading to insoluble plaques and other fibrotic structures that can themselves bind/entrap the iron that caused their formation. This bound iron can cause further hydroxyl radical formation such that the process is autocatalytic. Eventually this overwhelms cellular defences, leading to cell death (with further release of iron)Fig. 7Large (17-fold) accumulation of EPR-detectable iron in atherosclerotic plaques relative to healthy non-atherosclerotic ('intima') controls. The difference is highly significant (*P* = 0.0001). Data are replotted from those in Fig. 1b of Stadler et al. ([@CR1425])Fig. 8The major events accompanying sepsis and the Systemic Inflammatory Response Syndrome. Note in particular the positive feedback by which the release of pro-inflammatory cytokines and ROSs leads to the release of poorly liganded iron (e.g. from ferritin and haem) that causes the release of further inflammatory cytokines and ROSs. In principle, iron chelators could interfere with this vicious cycleFig. 9A diagram, based very loosely on the narrative in (Kohanski et al. [@CR814]), illustrating how the autocatalytic activity of the reactions of superoxide, peroxide and the hydroxyl radical involving poorly liganded iron can exert a positive feedback leading to the death of cellsFig. 10'Bow-tie' models of cellular networks. There are many examples of cellular networks in which a large variety of possible initial events leads to complex sequelae, but these are mediated via a comparatively small number of 'intermediate' reactions. While in the present case it is suggested that these in part involve complex positive feedbacks, the general 'bow-tie' idea does allow one to recognise that despite the many different possible inputs, a broadly unitary kind of mechanism of action---here involving iron dysregulation---can reasonably be invoked to explain the multiple causes that can lead to cell death and destructionFig. 11The three main iron chelators approved for clinical useFig. 12The extent of cell damage caused by the unliganded iron-catalysed production of ROSs and RNSs is determined by many factors, some of which promote and some of which act against it. While the existence of hormesis (see text) means that the see-saw illustrated here is an imperfect metaphor, the diagram serves to illustrate the complexity of the problem and the need for a systems biology approach to its solutionFig. 13The steady-state concentrations of a molecule depend on the rates of production and removal of the molecule in question. Both lowering creation and increasing removal represents a particularly effective strategy relative to doing just one of these alone. Thus if C is the hydroxyl radical we can lower its concentration by decreasing A and/or B and by increasing the rates of the reaction to D and E. The latter (decrease of concentration of C) may sometimes better be effected by increasing the activities of enzymes yet further downstreamFig. 14The relationship between 'forward' and 'inverse' methods of systems biology. The comparison of two 'inverse' systems (one a control and one treated with a toxin) in terms of the estimation of which parameters have changed most allows one to infer the sites or modes of action of that toxin \[In a related manner we also discriminate forward and reverse genetics, including chemical genetics (Kell [@CR762], [@CR763])\].$$\documentclass[12pt]{minimal}
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Superoxide (also produced by mitochondria) can react with ferric iron in the Haber-Weiss reaction (Kehrer [@CR761]) to produce Fe(II) again, thereby effecting redox cycling of the iron (Fig. [1](#Fig1){ref-type="fig"}):$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \hbox{O}_2^{\bullet -} $$\end{document}$ for reducing the Fe(III) to Fe(II) (Hershko and Weatherall [@CR625]), as can other reducing agents, and indeed too low a redox poise leads to DNA damage (e.g. Li and Marbán [@CR909]; Seifried et al. [@CR1360]).

The hydroxyl radical is exceptionally reactive and damaging to cellular components, and, for instance, can liberate further Fe(II) from iron-sulphur centres and other iron-containing compounds such as ferritin (Arosio et al. [@CR60]), thereby driving reaction (1) in an autocatalytic, runaway kind of reaction. This kind of phenomenon has the potential to overwhelm any kinds of attempts at repair, and inflammation and oxidative stress are the hallmarks of each of the conditions I summarise. Related reactions include peroxynitrite production (from the reaction of NO and superoxide) (Babior [@CR82]; Beckman et al. [@CR124]; Beckman and Koppenol [@CR126]; Goldstein and Merényi [@CR522]; Koppenol et al. [@CR826]; Murphy et al. [@CR1077]; Pacher et al. [@CR1144]; Pavlovic and Santaniello [@CR1173]; Pryor and Squadrito [@CR1227]; Radi et al. [@CR1243], [@CR1242]; Rubbo and O'Donnell [@CR1307]; Rubbo et al. [@CR1308]; Smith et al. [@CR1405]; Squadrito and Pryor [@CR1433]; Szabo [@CR1478]; Szabó et al. [@CR1479]; Torreilles et al. [@CR1517]; White et al. [@CR1624]; Zimmet and Hare [@CR1717]). These can lead to nitrotyrosine (Beckman [@CR123]; Goldstein and Merényi [@CR522]; Herce-Pagliai et al. [@CR623]) (a reaction catalysed by poorly liganded iron, Beckman et al. [@CR125]), or nitro-fatty acid (Aslan et al. [@CR65]; O'Donnell and Freeman [@CR1116]) production or protein cysteine nitrosylation (Lancaster [@CR863]; Landino [@CR864]; Vaz and Augusto [@CR1557]) that can provide a means of their detection downstream. Some of these are shown in Fig. [2](#Fig2){ref-type="fig"}. A key point here is that despite the widespread and uncritical use of the term ROS to describe any 'Reactive Oxygen Species', most such as superoxide and peroxide are not terribly reactive, in contrast to the hydroxyl radical (and peroxynitrite) which is, and **unliganded iron is required for hydroxyl radical production in the Fenton reaction**. Hence the focus on unliganded iron rather than the more nebulous ROSs, albeit that (su)peroxide is necessarily involved.

Clearly the occurrence of these activities leads to the (more or less irreversible) formation of a variety of substances that can act as biomarkers of these activities (Kell [@CR766]), and such oxidised compounds are represented by both small and macro-molecules. For instance, 8-hydroxy-2′-deoxyguanosine (8-OHdG) ([ChEBI 40304](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:40304)) also referred to as its tautomer 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) ([HMDB03333](http://www.hmdb.ca/metabolites/HMDB03333)) is produced when the hydroxyl radical reacts with DNA and damages it (e.g. Bal and Kasprzak [@CR91]; Burrows and Muller [@CR209]; Cooke et al. [@CR305], [@CR306]; Lloyd et al. [@CR933]; Loft and Poulsen [@CR934]; Orhan et al. [@CR1137]; Shi et al. [@CR1380]; Toyokuni and Sagripanti [@CR1521]; Valavanidis et al. [@CR1540]; Valko et al. [@CR1547]), and **body-iron status correlates rather strongly with its production or urinary excretion** (Agarwal et al. [@CR12]; Broedbaek et al. [@CR193]; Fujita et al. [@CR464], [@CR465]; Gackowski et al. [@CR471]; Hori et al. [@CR643]; Kang et al. [@CR737]; Kuo et al. [@CR851]; Maruyama et al. [@CR1000]; Nakano et al. [@CR1084]; Toyokuni and Sagripanti [@CR1521]; Tuomainen et al. [@CR1531]; Valavanidis et al. [@CR1541]). The data in (Hori et al. [@CR643]) relating urinary 8-OHdG levels to serum ferritin concentrations are particularly striking, and I have digitised them (cf. Pettifer et al. [@CR1197] for pointers to automated ways of doing this in the future) and replotted some of them in Fig. [3](#Fig3){ref-type="fig"}.

Ferritin levels (a common measure of body iron stores) are also widely associated with disease development/ severity/ poor outcomes (e.g. Alissa et al. [@CR33]; Armand et al. [@CR57]; Bartzokis et al. [@CR106]; Braun et al. [@CR185]; Bugianesi et al. [@CR204]; Chen et al. [@CR269]; Choi et al. [@CR277]; Double et al. [@CR377]; Fargion et al. [@CR413]; Fernández-Real et al. [@CR426]; Ford and Cogswell [@CR441]; Forouhi et al. [@CR442]; He et al. [@CR613]; Hubel et al. [@CR657]; Ishizaka et al. [@CR675]; Jehn et al. [@CR690], [@CR691]; Kaur et al. [@CR751]; Kiechl et al. [@CR790]; Lee et al. [@CR874]; Lim et al. [@CR918]; Rayman et al. [@CR1258]; Rouault [@CR1305]; Salonen et al. [@CR1316]; Sheth and Brittenham [@CR1379]; Tuomainen et al. [@CR1532]; Valenti et al. [@CR1545]; Wilson et al. [@CR1631]; You et al. [@CR1676]; You and Wang [@CR1677]) (Adamkiewicz et al. [@CR5]; Baune et al. [@CR115]; Busca et al. [@CR210]; DePalma et al. [@CR357]; Ferrara et al. [@CR431]; Ferrucci et al. [@CR433]; Gamberini et al. [@CR483]; Goodall et al. [@CR533]; Inati et al. [@CR669]; Kaysen [@CR757]; Knovich et al. [@CR809]; Kolberg et al. [@CR818]; Lecube et al. [@CR872]; Lim et al. [@CR919]; Mateo-Gallego et al. [@CR1007]; McNeill et al. [@CR1020]; Menke et al. [@CR1028]; Qureshi et al. [@CR1239]; Rajpathak et al. [@CR1245]; Sharifi et al. [@CR1371]; Skinner et al. [@CR1407]; Song et al. [@CR1425]; Storey et al. [@CR1453]; Sun et al. [@CR1470]; Tsimikas et al. [@CR1528]; Valenti et al. [@CR1544]; Walker et al. [@CR1579]; Wang et al. [@CR1591]; Yoneda et al. [@CR1674]; Zandman-Goddard and Shoenfeld [@CR1693]), though note that most assays are for the protein itself, and not for the full molecule including any iron that it may sequester effectively (Balla et al. [@CR92]; Hintze and Theil [@CR634]; Theil [@CR1504]) or otherwise.

Although iron is most commonly bivalent, Fe(II), or trivalent, Fe(III), this simple statement does not remotely cover the relevant chemistry and speciation that are necessary to recognise what forms of 'iron' may be safe and which are likely to catalyse damaging reactions. The first issue is that at neutral pH Fe(III) is more or less insoluble, and in aerobic environments it is necessary to chelate the otherwise 'free' Fe(III) with appropriate chelators or siderophores (especially for microbes, e.g. Andrews et al. [@CR55]; Barry and Challis [@CR104]; Cornelis and Andrews [@CR307]; de Carvalho and Fernandes [@CR346]; Haas et al. [@CR577]; Johnson [@CR709]; Miethke and Marahiel [@CR1035]; Raymond et al. [@CR1259]; Sandy and Butler [@CR1322]; Wandersman and Delepelaire [@CR1583]; Winkelmann [@CR1634]). These siderophores---secreted as are other bacterial pheromones (Kell et al. [@CR772])---typically have extremely tight binding constants (*K*~f~ \> 10^30^, e.g. Clifton et al. [@CR290]; Loomis and Raymond [@CR940]) and can solubilise and sequester iron such that it can be internalised via suitable transporter molecules within the plasma membrane (Stintzi et al. [@CR1446]).

Iron contains up to six individual chelation sites, arranged octahedrally, and ligands can typically satisfy them partially (i.e. some ligands are bidentate or tridentate and need three or two molecules for full liganding/activity) or fully i.e. are hexadentate. **Since iron cannot be transmuted into any other substance, the only way to stop the damaging activity of free or partially liganded 'iron' is to ensure that*all of its six possible liganding sites are satisfied*, whether by endogenous chelators or those added from the diet or as pharmaceuticals**. Put another way, it is not simply enough to know that 'iron' is present at an adequate level but that it is available*in a suitably liganded form*. **Anaemia can be caused by poor liganding as well as by an actual shortage of 'iron' itself**. Note too that*partial* chelation in the presence of an antioxidant agent such as ascorbate (vitamin C) can in fact make ascorbate (or other reducing agent) act as a*pro*-oxidant and thus actually*promote* the production of OH^•^ radicals in the presence of inappropriately or inadequately liganded Fe(II) (Allen and Cornforth [@CR36]; Fábián and Csordás [@CR405]; Halliwell [@CR588]; Hininger et al. [@CR632]; Lachili et al. [@CR858]; Long et al. [@CR939]; Miller et al. [@CR1041]; Reif [@CR1265]; Sugihara et al. [@CR1459]). This very likely explains the often and indeed surprisingly disappointing clinical results obtained when using antioxidants alone (Bjelakovic et al. [@CR157]; Giustarini et al. [@CR515]; Kell [@CR766]; Miller et al. [@CR1042]).

The above facts are well known (e.g. Halliwell and Gutteridge [@CR589]; Weinberg [@CR1607]), and I discussed them at length in a recent and wide-ranging review (Kell [@CR766]). My purpose here is to look more closely at the evidence that they are part of the sequelae of a number of predispositions to cellular and organismal death (whether by necrosis or apoptosis) that follow from a large variety of initial 'insults' or distal causes, whether of genetic or environmental origin (or both). While, as a systems property, many other cellular processes contribute measurably to any specific activity, **I suggest, in all the disparate cases I review, that it is the binding of poorly liganded iron (mainly bivalent) to inappropriate cellular structures that serves to generate this catalytic activity, albeit that the overall manifestations may differ at a physiological level, and I here review what evidence is available. This basic suggestion can be tested explicitly more or less easily.** I suggest further that it is this ongoing, autocatalytic activity based on positive feedback that is responsible for the really large-scale damage, leading to organismal death, that can occur in affected cells, tissues, organs and organisms. **This analysis also suggests an important role for iron chelation as part of combination approaches in the acute and chronic therapy of these conditions.** An overview of this article is given as a Mind Map (Buzan [@CR219]) in Fig. [4](#Fig4){ref-type="fig"}.

Note that I do recognise that other transition and polyvalent metal ions (Al^n+^, Cr^n+^, Cu^n+^, Mn^n+^, Se^n+^, Zn^n+^ etc.) may also contribute to the kinds of process I describe. However, for reasons of simplicity, focus, and because of the natural abundance of this metal in biological systems, it is 'iron' on which I shall concentrate. As previously (Kell [@CR766]), **I use the term 'iron' to include iron of any valencies or speciation**, unless specified otherwise.

Since the role of iron is obvious in cases of primary diseases of iron overload, such as hereditary haemochromatosis (e.g. Camaschella and Merlini [@CR230]; Ellervik et al. [@CR397]; Gan et al. [@CR485]; Limdi and Crampton [@CR920]; Mair and Weiss [@CR974]; Marx [@CR1001]; McLaren and Gordeuk [@CR1018]; Pantopoulos [@CR1155]; Papanikolaou and Pantopoulos [@CR1157]; Pietrangelo [@CR1202]; Weiss [@CR1615]), thalassaemias (e.g. Borgna-Pignatti et al. [@CR173]; Camaschella and Merlini [@CR230]; Cao and Galanello [@CR233]; Cohen et al. [@CR292]; Gattermann [@CR491]; Lam et al. [@CR861]; Li et al. [@CR905]; Mohkam et al. [@CR1058]; Peng et al. [@CR1176]; Taher et al. [@CR1483]; Vichinsky et al. [@CR1563]) and myelodysplastic syndrome (e.g. Cazzola et al. [@CR251]; Cuijpers et al. [@CR328]; Dreyfus [@CR381]; Gattermann [@CR490]; Greenberg [@CR555]; Greenberg et al. [@CR556]; Jabbour et al. [@CR677]; Jädersten and Hellström-Lindberg [@CR680]; Leitch [@CR893]; Mahesh et al. [@CR971]; Malcovati [@CR976]; Porter et al. [@CR1215]; Wimazal et al. [@CR1633]), I largely ignore this literature. However, I recognise that the sequelae of iron overload, especially various kinds of organ failure, share many similarities to those I describe below, consistent with the role of iron in these other cases where its involvement has been less widely recognised. Clearly the commonality of any specific effect with those of known iron overload (Dever et al. [@CR361]) might give strong hints for the involvement of iron in specific toxicological processes.

The literature survey at the time of initial submission for review extended to 14 June, 2010.

To start our survey, we look at the consequences of an acute cerebral infarction or stroke.

Stroke {#Sec2}
======

Stroke is a term used to describe the destruction of brain cells, typically following a temporary blockage in blood flow (ischaemia-reperfusion injury) or an intra-cranial haemorrhage. The extent of damage varies considerably, and can be exacerbated because affected cells can release inflammatory cytokines that activate other cells in a similar way, providing a positive autocatalytic effect and leading to spreading of the damage. It is this secondary spreading that is especially damaging, but because it is slower (4--7days), it also affords the opportunity for therapeutic intervention (Qureshi et al. [@CR1238]). It is now clear that iron is intimately involved (Armengou and Davalos [@CR58]; Bailey et al. [@CR85]; Bishop and Robinson [@CR153]; Chang et al. [@CR259]; Dávalos, et al. [@CR340]; Demougeot et al. [@CR355]; Ferro and Dávalos [@CR432]; Garoufi et al. [@CR489]; Gillum et al. [@CR512]; Lee et al. [@CR880]; Marniemi et al. [@CR996]; Mascitelli and Pezzetta [@CR1003]; Mehta et al. [@CR1024]; Mu et al. [@CR1070]; Nakamura et al. [@CR1083]; Saxena et al. [@CR1332]; Selim and Ratan [@CR1362]; Switzer et al. [@CR1477]; Wagner et al. [@CR1576]; Wu et al. [@CR1646]; Zuliani et al. [@CR1720]; Adams [@CR7]; Altamura et al. [@CR38]; Assenza et al. [@CR66]; Basak et al. [@CR107]; Bosomtwi et al. [@CR176]; Carbonell and Rama [@CR236]; Cho et al. [@CR273]; Ekblom et al. [@CR394]; Hanson et al. [@CR595]; Heckl [@CR616]; Helal [@CR621]; Jolkkonen et al. [@CR711]; Justicia et al. [@CR718]; Kaushal and Schlichter [@CR754]; Kim et al. [@CR791]; Kobayashi et al. [@CR811]; Lou et al. [@CR947]; Maguire et al. [@CR969]; Mazumdar et al. [@CR1014]; Mehdiratta et al. [@CR1022]; Millan et al. [@CR1039], [@CR1038]; Millerot-Serrurot et al. [@CR1044]; Nighoghossian et al. [@CR1103]; O'Rourke et al. [@CR1121]; Ratan et al. [@CR1251]; Ross and Meschia [@CR1301]; Saleh et al. [@CR1315]; Santhosh et al. [@CR1324]; Verduzco and Nathan [@CR1562]; Walters and Rye [@CR1581]; Weng et al. [@CR1617]), whether by release from (ferritin in) cells or from the haem of haemoglobin. Iron chelators have thus shown promise in decreasing the sequelae of an initial stroke-inducing event (Demougeot et al. [@CR355]; Ferro and Dávalos [@CR432]; Hurn et al. [@CR661]; Kompala et al. [@CR820]; Mu et al. [@CR1070]; Patt et al. [@CR1171]; Prass et al. [@CR1220]; Selim and Ratan [@CR1362]; Soloniuk et al. [@CR1424]; White et al. [@CR1623]; Chen-Roetling et al. [@CR264]; Gu et al. [@CR562]; Hanson et al. [@CR595]; Hua et al. [@CR652]; Mazumdar et al. [@CR1014]; Méthy et al. [@CR1031]; Millerot-Serrurot et al. [@CR1044]; Mirre et al. [@CR1050]; Okauchi et al. [@CR1128], [@CR1127]; Ratan et al. [@CR1251]; Robinson et al. [@CR1288]; Selim [@CR1361]; Verduzco and Nathan [@CR1562]), providing further evidence for the primary importance of iron in causing injury.

While stroke is a sudden occurrence, albeit with secondary consequences, a number of neurodegenerative diseases are rather more long term in their development, and we now look at several, each of which is seen to involve iron intimately.

Huntington's disease {#Sec3}
====================

The pathology of HD reveals striking neurodegeneration in the corpus striatum and shrinkage of the brain, leading to its most prominent manifestation, viz. movement disorders or chorea (Bhidayasiri and Truong [@CR147]). Huntington's disease occurs via the addition of trinucleotide CAG repeats within exon 1 of the relevant gene, encoding (poly)glutamine (polyQ) repeats in the huntingtin protein (htt) and leading to a gain of (toxic) function (Bauer and Nukina [@CR114]; Gusella and MacDonald [@CR569]; Imarisio et al. [@CR665]; Quintanilla and Johnson [@CR1237]). The number of these repeats determines both the time of onset of observable disease (more repeats meaning earlier onset) (Perutz and Windle [@CR1192]; Ross [@CR1300]; Walters and Murphy [@CR1582]), accounting for 70% of the variance (Imarisio et al. [@CR665]), and the disease severity, implying that it is indeed the polyglutamines*themselves* that are the chief culprits. Some of the polyQ-containing huntingtin proteins can also aggregate to form inclusion bodies, and aggregation and neurodegeneration can in part be related (Chopra et al. [@CR280]; Cowan et al. [@CR311]; Michalik and Van Broeckhoven [@CR1033]; Nagai et al. [@CR1080]; Wang et al. [@CR1587], [@CR1584]; Zhang et al. [@CR1692]). Now the evidence for the involvement of poorly liganded iron in a wide variety of neurodegenerative diseases is overwhelming (e.g. Benarroch [@CR131]; Bishop et al. [@CR151]a; Brown [@CR195]; Friedman et al. [@CR459]; Jellinger [@CR693]; Ke and Qian [@CR759]; Kell [@CR766]; Lee et al. [@CR875]; Perez and Franz [@CR1183]; Thompson et al. [@CR1511]; Youdim et al. [@CR1668]; Zecca et al. [@CR1698]), and the question arises as to whether huntingtin (or, more likely, its degradation fragments), containing these polyQ tracts, can catalyse oxidative stress and/or hydroxyl formation directly. In an important paper, Firdaus et al. (Firdaus et al. [@CR439]) show that that huntingtin inclusion bodies act as centres of oxidative stress and that partially purified inclusion bodies contain large amounts of oxidised proteins. Iron metabolism is deranged in gene knockdown models of Huntington's (Henshall et al. [@CR622]; Lumsden et al. [@CR954]), and experiments with the iron chelator deferroxamine revealed that the oxidation, localisation and structural organisation of the inclusion bodies formed by mutant htt were indeed irondependent. They did not demonstrate the ability of these inclusion bodies to catalyse hydroxyl formation, but this could easily be shown using specific assays, such as the hydroxylation of suitable aromatics (e.g. Grootveld and Halliwell [@CR560]; Halliwell and Gutteridge [@CR589]; Thomas et al. [@CR1495]). The iron chelator clioquinol is also protective (Nguyen et al. [@CR1101]).

Parkinson's disease {#Sec4}
===================

Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra part of the brain and is characterised in particular by the presence of intracytoplasmic inclusions from protein aggregates called Lewy bodies (LB) and at the physiological level by a variety of movement disorders (e.g. Singh et al. [@CR1405]). It is strongly linked with oxidative stress (e.g. Alam et al. [@CR29]; Büeler [@CR203]; Jenner [@CR696]; Jenner and Olanow [@CR697]; Kidd [@CR789]; Mandel et al. [@CR986]; Olivares et al. [@CR1134]; Seet et al. [@CR1358]; Van Laar and Berman [@CR1550]; Zhang et al. [@CR1701]). Again (e.g. Berg et al. [@CR138]; Bharath et al. [@CR145]; Buchanan et al. [@CR202]; Bush [@CR211]; Castellani et al. [@CR244]; Double et al. [@CR377]; Good et al. [@CR530]; Gotz et al. [@CR543]; Hirsch and Faucheux [@CR637]; Jellinger [@CR693]; Johnson [@CR710]; Olanow and Arendash [@CR1132]; Ostrerova-Golts et al. [@CR1140]; Sofic et al. [@CR1422]; Wolozin and Golts [@CR1638]; Altamura and Muckenthaler [@CR39]; Andersen [@CR49]; Barapatre et al. [@CR98]; Baudrexel et al. [@CR112]; Becker [@CR119]; Becker et al. [@CR120], [@CR121]; Berg [@CR136], [@CR137]; Berg and Hochstrasser [@CR139]; Berg et al. [@CR140][@CR141]; Brar et al. [@CR181]; Brown [@CR196]; Crichton and Ward [@CR320]; Fasano et al. [@CR414]; Friedman et al. [@CR459], [@CR460]; Ghosh et al. [@CR505]; Hirsch [@CR636]; Jellinger [@CR695]; Jimenez-Del-Rio et al. [@CR703]; Kaur and Andersen [@CR749]; Lee and Andersen [@CR875]; Levenson [@CR897]; Mandemakers et al. [@CR991]; Matusch et al. [@CR1013]; Oakley et al. [@CR1122]; Salvador [@CR1319]; Shi et al. [@CR1381]; Wayne Martin [@CR1603]; Wypijewska et al. [@CR1650]; Yeager and Coleman [@CR1664]; Zecca et al. [@CR1698]; Zhang et al. [@CR1693], [@CR1690])---there is overwhelming evidence for the involvement of iron in this neurodegeneration. Why these dopaminergic neurons are especially susceptible is not entirely clear, although dopamine is capable of reacting with iron directly to form a toxic complex (Arreguin et al. [@CR61]; Paris et al. [@CR1158]) that probably itself catalyses hydroxyl formation. Iron chelators inhibit these inimical processes (Gal et al. [@CR473]; Perez et al. [@CR1170]; Xu et al. [@CR1642]; Youdim et al. [@CR1667], [@CR1668]; Zheng et al. [@CR1713]), including (Kaur et al. [@CR752]; Reznichenko et al. [@CR1260]; Youdim [@CR1678]) in the case of a Parkinson-like disease induced (Blum et al. [@CR161]; Choi et al. [@CR278]; Gal et al. [@CR474]; Yokoyama et al. [@CR1661]) by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) ([ChEBI 17963](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17963)). The Lewy bodies contain lipid and a variety of proteins, including ubiquitin, neurofilament, various proteasomal elements and α-synuclein, which may be oxidatively modified (Double et al. [@CR375]). Ferric iron may itself catalyse the formation of α-synuclein oligomers (Brown [@CR195]; Hillmer et al. [@CR630]; Peng et al. [@CR1167]), and copper may also be involved (Wang et al. [@CR1580]).

Melanins are polymers of polyphenols, especially of L-dopamine, although neuromelanin, which also contains oxidatively polymerised dopamine or noradrenaline with the possible involvement of cysteinylderivatives (Fedorow et al. [@CR420]), is of special interest here. The substantia nigra also contains a substantial amount of the dark, insoluble polymeric pigment neuromelanin, and this has been shown directly to bind (and release) iron in high amounts (Double et al. [@CR374], [@CR376]; Fasano et al. [@CR414]; Faucheux et al. [@CR417]; Gerlach et al. [@CR501], [@CR500]; Shamoto-Nagai et al. [@CR1367]), and thereby to produce an iron-loaded form that seems to serve as a reservoir catalysing (hydroxyl) radical formation and whose amounts correlate with PD. In this case, the in vitro experiments have been done, and incubation of human neuromelanin with iron in vitro stimulates oxidative tissue damage (Ben-Shachar et al. [@CR129]; Double et al. [@CR501]; Gerlach et al. [@CR502]).

Another dark pigment commonly observed in PD patients (and other neurodegenerative diseases) is lipofuscin (Double et al. [@CR375]; Jung et al. [@CR712]; Terman and Brunk [@CR1498]). Lipofuscin too consists of lipids and oxidised proteins, often crosslinked by oxidised lipid derivatives such as (E)-4-hydroxy-non-2-enal ([ChEBI 58968](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:58968)) and can adsorb high contents of metals (including iron) of up to 2% by weight (Jung et al. [@CR715]). It is typically formed in lysosomes from degrading mitochondria (Terman et al. [@CR1487]), themselves rich in metalloproteins, and the inability of cells to degrade it means that (purportedly) non-dividing cells (such as brain tissue) simply accumulate it as cells age (Terman and Brunk [@CR1498], [@CR1499]). This arguably explains why non- or rarely-dividing tissues such as brain tissues are particularly susceptible, though note the important and increasing evidence (e.g. Abrous et al. [@CR4]; Christie and Cameron [@CR283]; Demir et al. [@CR352]; Fuchs and Gould [@CR462]; Götz and Huttner [@CR542]; Gould [@CR544]; Imayoshi et al. [@CR663]; Leuner et al. [@CR544]; Lledo et al. [@CR928]; Ohnuma and Harris [@CR1126]; Taupin [@CR1492]; Zhao et al. [@CR1695]) for considerable turnover---neurogenesis---in at least some regions of the brain. The **autocatalytic nature** of the process---lipofuscin loaded with iron catalyses more lipofuscin production---is especially dangerous and can (as one would predict) be inhibited using appropriate iron chelators (Persson et al. [@CR1178]). Iron chelation also assists neurogenesis (Nowicki et al. [@CR1109]).

Thus, as with Huntington's, Parkinson's disease is clearly characterised by all the hallmarks of hyperactive hydroxyl radical generation, leading to cell death and destruction, in this case mainly, it would seem (Chen et al. [@CR265]; Chiueh et al. [@CR270]; Ekshyyan and Aw [@CR395]; Jellinger [@CR694]; Jenner [@CR696]; Jenner and Olanow [@CR697]; Kermer et al. [@CR780]; Levenson [@CR898]; Loh et al. [@CR933]; Mandel et al. [@CR984]; Mattson [@CR1010]; Okouchi et al. [@CR1116]; Xu et al. [@CR1641]; Yasuda and Mochizuki [@CR1663]), by apoptosis.

Gaucher's disease {#Sec5}
-----------------

Gaucher's disease is an autosomally recessive inborn error of metabolism due to deficiency of a lysosomal enzyme, glucocerebrosidase (GBA), resulting in the accumulation of glucocerebroside in large macrophages throughout the reticuloendothelial system, leading to various neuronopathies. Given that the lysosome is the site of most labile iron in the cell (Fakih et al. [@CR408]; Gorria et al. [@CR541]; Kurz et al. [@CR851][@CR853], [@CR854]; Persson [@CR1190]; Tenopoulou et al. [@CR1483]; Terman et al. [@CR1488]; Yu et al. [@CR1669]), it is also of interest that there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson's disease (e.g. Aharon-Peretz et al. [@CR22]; Clark et al. [@CR288]; Gan-Or et al. [@CR484]; Lwin et al. [@CR955]), and vice versa (Sidransky et al. [@CR1389]). Iron dysregulation is also well established in Gaucher's disease (Finch et al. [@CR435]; Lee et al. [@CR882], [@CR883]; Lorber [@CR942], [@CR943]; Morgan et al. [@CR1062]; Schiano et al. [@CR1327]; Weisberger et al. [@CR1601]). This recognition of the role of iron dysregulation in Gaucher's disease may offer novel therapeutic approaches.

Alzheimer's disease {#Sec6}
===================

Alzheimer's disease (AD), the commonest of the neurodegenerative disease of ageing, shares many similarities with Huntington's and Parkinson's diseases, not least the extensive evidence for the role of oxidative stress (e.g. Butterfield et al. [@CR217]; Christen [@CR282]; DiMauro and Schon [@CR367]; Good et al. [@CR529]; Milton [@CR1046]; Miranda et al. [@CR1049]; Moreira et al. [@CR1059]; Nunomura et al. [@CR1114], [@CR1113]; Reddy and Beal [@CR1261]; Reddy et al. [@CR1262]; Rottkamp et al. [@CR1304]; Smith et al. [@CR1417], [@CR1406]; Zhu et al. [@CR1701]) and of iron (e.g. Adlard and Bush [@CR10]; Avramovich-Tirosh et al. [@CR73]; Becker et al. [@CR120]; Bishop et al. [@CR154]; Blázquez et al. [@CR160]; Bolognin et al. [@CR164]; Brar et al. [@CR181]; Bush [@CR211], [@CR212], [@CR213]; Casadesus et al. [@CR240]; Castellani et al. [@CR243]; Collingwood and Dobson [@CR295]; Collingwood et al. [@CR296]; Connor and Lee [@CR300]; Ding et al. [@CR368]; Doraiswamy and Finefrock [@CR373]; Gerlach et al. [@CR498]; Good et al. [@CR532]; Hegde et al. [@CR617]; Honda et al. [@CR637]; Jellinger et al. [@CR89]; Jellinger [@CR695]; Kala et al. [@CR723]; Lehmann et al. [@CR891]; LeVine [@CR901]; Lovell et al. [@CR945]; Malecki and Connor [@CR977]; Mandel et al. [@CR982]; Markesbery [@CR993]; Markesbery and Lovell [@CR994]; Mascitelli et al. [@CR1001]; Olanow and Arendash [@CR1132]; Ong and Farooqui [@CR1136]; Quintana et al. [@CR1236]; Rival et al. [@CR1286]; Robson et al. [@CR1289]; Silvestri and Camaschella [@CR1394]; Smith et al. [@CR1403], [@CR1420]; Tabner et al. [@CR1468]; Thomas and Jankovic [@CR1508]; Thompson et al. [@CR1511]; Valko et al. [@CR1547]; Zatta et al. [@CR1684]; Zecca et al. [@CR1698]; Zheng et al. [@CR1713]). It is especially noteworthy that iron correlates with disease severity as measured by cognitive ability (Ding et al. [@CR368]; Gómez Ravetti et al. [@CR523]; Grossi et al. [@CR561]; Lavados et al. [@CR867]; Perez et al. [@CR1186]; Smith et al. [@CR1420]). AD is characterized by the loss of neurons in the cognitive centres of the brain and by the presence of two separate pathological lesions, extracellular β-amyloid (Aβ) plaques (e.g. Dong et al. [@CR372]; Scott and Orvig [@CR1355]) and neurofibrillary tangles within neurons (Shcherbatykh and Carpenter [@CR1375]).

Again, there is evidence that insoluble polymers (fibrillary tangles) of proteins such as the β-amyloid can bind iron (Castellani et al. [@CR243]; Dickens and Franz [@CR365]; Exley [@CR403]; Good et al. [@CR528]; Jiang et al. [@CR700]; Mancino et al. [@CR981]; Rival et al. [@CR1286]; Sayre et al. [@CR1322]; Smith et al. [@CR1402]) and thereby act in an autocatalytic manner to promote further radical production and oxidative stress. There is a also relationship between the ability to bind haem and neurotoxicity (Atamna [@CR67]; Atamna et al. [@CR68]), and (HFE) mutations that cause haemochromatosis increase the susceptibility to AD (Bartzokis et al. [@CR105]; Candore et al. [@CR232]; Combarros et al. [@CR298]; Connor and Lee [@CR300]; Haacke et al. [@CR574]; Kauwe et al. [@CR755]; Lleó et al. [@CR932]; Moalem et al. [@CR1056]; Pulliam et al. [@CR1229]; Robson et al. [@CR1289]; Sampietro et al. [@CR1320]), especially when in the presence of the APOE4 allele (Pulliam et al. [@CR1229]). (HFE mutations also increase susceptibility to PD (Biasiotto et al. [@CR148]; Dekker et al. [@CR352])---but cf. (Aamodt et al. [@CR1])---and to ALS (Ellervik et al. [@CR397])).

Importantly, iron chelators have been shown to ameliorate the development of fibril formation/neurodegeneration/dementia/AD (Amit et al. [@CR45]; Avramovich-Tirosh et al. [@CR73]; Bandyopadhyay et al. [@CR93]; Barnham et al. [@CR102]; Biran et al. [@CR150]; Bolognin et al. [@CR163]; Crapper McLachlan et al. [@CR319]; Cuajungco et al. [@CR211]; Faux et al. [@CR418]; Finefrock et al. [@CR435]; Liu et al. [@CR922], [@CR923], [@CR924]; Mancino et al. [@CR984]; Mandel [@CR985], [@CR987]; Reznichenko et al. [@CR1271]; Scott and Orvig [@CR1355]; Weinreb et al. [@CR1600]; Zheng et al. [@CR1713]). Although this fact rarely appears in papers setting out therapeutic options for preventing (or at least ameliorating the progress of) AD, this already considerable literature suggests that trials using modern iron chelators would be of worth.

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) {#Sec7}
=========================================================

ALS is another neurodegenerative disease in which iron has been strongly implicated (and thus the same kinds of mechanism as described previously) (Bush [@CR211]; Carri et al. [@CR237]; Cozzolino et al. [@CR316]; Goodall et al. [@CR533]; Jeong et al. [@CR698]; Kasarskis et al. [@CR743]; Mattson [@CR1009]; Migliore et al. [@CR1036]; Molfino et al. [@CR1057]; Qureshi et al. [@CR1239]; Reynolds et al. [@CR1256]; Sadrzadeh and Saffari [@CR1309]; Sayre et al. [@CR1321]; Scott and Orvig [@CR1355]; Spasojević et al. [@CR1430]; Sutedja et al. [@CR1475]; Wang et al. [@CR1594]). Again, the clear benefits of iron chelators in mouse models (Jeong et al. [@CR698]; Petri et al. [@CR1194]) and elsewhere (Avramovich-Tirosh et al. [@CR810]; Bolognin et al. [@CR163]) would seem to merit trials in humans known to be at risk. Long-standing associations of some forms of ALS with mutations in genes coding for superoxide dismutase 1 (e.g. Dalle-Donne [@CR337]; Pasinelli and Brown [@CR1165]; Rosen et al. [@CR1299]; Vucic and Kiernan [@CR1573]; Wijesekera and Leigh [@CR1626]) are consistent with this, and recent genetic associations (e.g. Kwiatkowski Jr. et al. [@CR856]; Valdmanis et al. [@CR1529]; Vance et al. [@CR1553]) include one with optineurin (Maruyama et al. [@CR999]) that together with other evidence implies an interaction with NF-κB (see later) leading to the downstream effects of apoptotic neuronal cell death.

Friedreich's ataxia {#Sec8}
===================

Friedreich's ataxia is another neurodegenerative disease caused by the insertion of a trinucleotide repeat (or occasionally a missense mutation) in the gene encoding a protein called frataxin (Adibhatla and Hatcher [@CR9]; Babady et al. [@CR80]; Becker and Richardson [@CR118]; Bencze et al. [@CR132]; Chakravarty [@CR256]; González-Cabo et al. [@CR525]; Palau [@CR1147]; Pandolfo [@CR1152]; Patel and Isaya [@CR1168]; Puccio [@CR1228]; Rötig et al. [@CR1290]; Santos et al. [@CR1325]; Sheftel et al. [@CR1364]). Driven not least by studies in bacteria and lower eukaryotes (Ayala-Castro et al. [@CR76]; Becker and Richardson [@CR118]; Bulteau et al. [@CR207]; Cavadini et al. [@CR247]; Cook et al. [@CR303]; De Freitas et al. [@CR347]; Foury [@CR446]; Foury and Cazzalini [@CR447]; Foury and Talibi [@CR448]; González-Cabo et al. [@CR526]; Irazusta et al. [@CR670], [@CR671]; Knight et al. [@CR807]; Pastore et al. [@CR1153]; Vázquez-Manrique et al. [@CR1558]; Wang and Craig [@CR1590]; cf. Seguin, et al. [@CR1359]), it is now understood that frataxin is a mitochondrial iron chaperone protein (Atkinson and Winge [@CR71]; Ba et al. [@CR78]; Babady et al. [@CR80]; Bencze et al. [@CR133]; Cavadini et al. [@CR248]; Correia et al. [@CR307]; Gakh et al. [@CR474]; Haugen et al. [@CR607]; Huang et al. [@CR650]a; Huang et al. [@CR655]; Karlberg et al. [@CR140]; Kondapalli et al. [@CR822]; Lill [@CR915]; Lill and Muhlenhoff [@CR916]; Lu and Cortopassi [@CR949]; MacKenzie et al. [@CR962]; Mandemakers et al. [@CR991]; Marmolino and Acquaviva [@CR995]; Napier et al. [@CR1082]; Napoli et al. [@CR1086]; O'Neill et al. [@CR1120]; Pandolfo [@CR1152]; Pandolfo and Pastore [@CR1153]; Pastore et al. [@CR1166]; Reddy [@CR1260]; Schagerlöf et al. [@CR1338]; Sparaco et al. [@CR1429]; Wilson [@CR1632]; Zanella et al. [@CR1694]) involved in the safe insertion of Fe(II) during the production of Fe--S centres in the mitochondrial respiratory chain (Anderson et al. [@CR50]). The defect thus leads to the liberation of mitochondrial iron (Huang et al. [@CR655]; Popescu et al. [@CR1200]; Richardson et al. [@CR655]). Fenton chemistry is strongly implicated (Park et al. [@CR1161]; Sturm et al. [@CR1456]), as the attenuation of H~2~O~2~ production (but not of superoxide) (Anderson et al. [@CR50]) ameliorates the disease (Anderson et al. [@CR51]). As would be expected, appropriate iron chelation may have therapeutic benefits (Boddaert et al. [@CR162]; Campanella et al. [@CR231]; Goncalves et al. [@CR524]; Kakhlon et al. [@CR722]; Lim et al. [@CR914]; Marmolino and Acquaviva [@CR995]; Santos et al. [@CR1325]; Schulz et al. [@CR1353]; Sohn et al. [@CR1410]). This very clear molecular picture underlines strongly the problems of iron release leading to cell death and destruction.

Multiple sclerosis {#Sec9}
==================

MS is an inflammatory demyelinating autoimmune disease affecting the CNS. While its underlying causes remain uncertain, and do not seem to have a significant genetic component (Baranzini et al. [@CR97]; Oksenberg et al. [@CR1117]; Ramagopalan et al. [@CR1246]), ROS are certainly implicated (Adibhatla and Hatcher [@CR9]), and antioxidant therapies may be useful (Mirshafiey and Mohsenzadegan [@CR1051]). It is at least plausible that part of the demyelination is caused by ROS and in particular hydroxyl radicals, and it is thus of much interest that iron dysregulation and/or deposition have indeed been implicated directly (Adams [@CR6]; Bakshi et al. [@CR88], [@CR87], [@CR87], [@CR90]; Bermel et al. [@CR143]; Brass et al. [@CR182], [@CR183]; Ceccarelli et al. [@CR252], [@CR253]; Chard and Miller [@CR261]; Craelius et al. [@CR317]; Drayer et al. [@CR378]; Eissa et al. [@CR393]; Exley et al. [@CR404]; Filippi and Agosta [@CR434]; Ge et al. [@CR493]; Grimaud et al. [@CR559]; Haacke et al. [@CR574], [@CR576], [@CR572]; Hammond et al. [@CR591]; He and Yablonskiy [@CR614]; Khalil et al. [@CR785]; LeVine and Chakrabarty [@CR902]; Neema et al. [@CR1090], [@CR1091], [@CR1088], [@CR1089]; Pirko et al. [@CR1192]; Sayre et al. [@CR1320]; Schenck and Zimmerman [@CR1339]; Simka and Rybak [@CR1395]; Singh and Zamboni [@CR1403]; Stankiewicz et al. [@CR1439]; Tjoa et al. [@CR1502]; Walter et al. [@CR1567]; Zamboni [@CR1691]; Zivadinov and Bakshi [@CR1718]; Zivadinov and Minagar [@CR1719]). While the extent of causality of the iron dysregulation in MS is not yet established, it is highly pertinent that iron chelators have been shown to suppress disease progression in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (Bowern et al. [@CR1176]; Mitchell et al. [@CR1053]; Pedchenko and LeVine [@CR1174]). To say the least, the question of the involvement of iron in the human disease would seem to need pursuing with some urgency.

Age-related macular degeneration {#Sec10}
================================

While this review is intended to be much more circumscribed than the previous one (Kell [@CR766]), there are some pertinent diseases in which my understanding has improved significantly, and age-related macular degeneration is one such. Age-related macular degeneration (AMD) (Rattner and Nathans [@CR1255]) is recognised as the leading cause of blindness and visual disability in the elderly in developed countries (Fine [@CR436]; Harvey [@CR602]; Lotery and Trump [@CR946]; Tielsch et al. [@CR1501]). Interestingly, despite the relatively modest impact of genome-wide association studies to date (Maher [@CR970]; Moore et al. [@CR1061]), and notwithstanding their promise as their statistical power improves, 80% of the variation in susceptibility to AMD is said to be explainable (Collins [@CR297]) (and see e.g. Chu et al. [@CR283]) though cf. e.g. (Chen et al. [@CR268]; Hadley et al. [@CR580]; Katta et al. [@CR746]; Neale et al. [@CR1090]; Patel et al. [@CR1154]; Sobrin et al. [@CR1421]) by just two genes concerned with inflammation combined with two environmental factors (smoking and obesity). The environmental factors can certainly be related to iron dysregulation. Indeed, as previously discussed, iron is significantly implicated in AMD (and other related diseases such as glaucoma) (Blasiak et al. [@CR158]; Cai et al. [@CR220]; Charkoudian et al. [@CR262]; Chen et al. [@CR264]; Chowers et al. [@CR281]; Dentchev et al. [@CR354]; Dunaief [@CR386]; García-Castiñeiras [@CR487]; Goralska et al. [@CR532], [@CR533], [@CR534]; Hahn et al. [@CR581], [@CR585]; He et al. [@CR613]; Loh et al. [@CR932]; Richer et al. [@CR1264]; Wong et al. [@CR1631]), iron chelation may help to reverse the process (Voloboueva et al. [@CR1558]), and dietary and other antioxidants are also protective (see Tan et al. [@CR1485]; Wang et al. [@CR1580]).

Prion diseases: including transmissible spongiform encephalopathies and Creutzfeldt--Jakob disease {#Sec11}
==================================================================================================

A particularly striking set of diseases, where the downstream events manifest as extreme cellular destruction leading to large areas of (brain) tissue disappearing completely, are represented by the prion diseases, in particular the TSEs including bovine spongiform encephalopathy (BSE) (e.g. Aguzzi et al. [@CR18]a; Aguzzi and Heikenwälder [@CR19]; Caughey and Baron [@CR246]; Caughey and Lansbury [@CR247]; Linden et al. [@CR922]) and scrapie (e.g. Bulgin and Melson [@CR206]; Hur et al. [@CR660]; Roostaee et al. [@CR1283]; Wisniewski and Sigurdsson [@CR1636]), kuru (Gajdusek [@CR473]; McLean [@CR1019]) and CJD (e.g. McLean [@CR1019]; Peden and Ironside [@CR1175]) (note too the co-location of amyloid plaques and spongiform degeneration in CJD, Ghoshal et al. [@CR509]).

Now it is well known that prion diseases are caused in part (or at least accompanied by) the conversion of the prion protein PrP from its normal form PrP^C^ to a conformationally distinct version PrP^Sc^ and that the latter can autocatalyse this conversion (Aguzzi and Heikenwälder [@CR19]; Aguzzi et al. [@CR21]b; Prusiner [@CR1225], [@CR1226]; Tamgüney et al. [@CR1484]; Watts and Westaway [@CR1602]). However, PrP^Sc^ levels are in many cases poorly correlated with prion disease progression, suggesting that it is necessary but not sufficient; 'something else' is required (Caughey and Baron [@CR246]). Equally, it is far from clear how a simple conformational change of a protein leads to the vacuolation or spongiosis (e.g. Aguzzi [@CR17]; Aguzzi et al. [@CR20]; Armstrong et al. [@CR59]; Chung et al. [@CR285]; Crozet et al. [@CR322]; Diedrich et al. [@CR369]; Foster et al. [@CR443]; Julius et al. [@CR714]; Kourie [@CR838]; Mallucci et al. [@CR978]; Mallucci et al. [@CR979]; Miele et al. [@CR1031]; Sakudo and Ikuta [@CR1313], [@CR1314]; Westaway et al. [@CR1620]; Williams et al. [@CR1617]) (formation of holes) in brain tissue characteristic of late-stage prion disease (and indeed of Alzheimer's (Erkinjuntti et al. [@CR400]; Sakudo and Ikuta [@CR1313]). The question then arises as to whether it is possible that PrP^Sc^ modifies iron metabolism in an unfavourable way (and/or vice versa), not least since prion proteins bear phylogenetic relationships to the ZIP family of metal ion transporters (Schmitt-Ulms et al. [@CR1331]). Building on earlier work relating prion biology with (especially) iron-induced oxidative stress (e.g. Bareggi et al. [@CR99]; Barnham et al. [@CR101]; Basu et al. [@CR110]; Choi et al. [@CR422]; Fernaeus et al. [@CR420], [@CR422]; Fernaeus and Land [@CR423]; Iwamaru et al. [@CR676]; Kim et al. [@CR795], [@CR794], [@CR791]; Lee et al. [@CR878]; Lehmann [@CR892]; Milhavet and Lehmann [@CR1037]; Pamplona et al. [@CR1149]; Park et al. [@CR1151]; Petersen et al. [@CR1193]; Pollera et al. [@CR1210]; Rana et al. [@CR1236]; Stegmann and Grohmann [@CR1442]; Westergard et al.[@CR1608]; Wong et al.[@CR1628]), this is exactly what Singh and colleagues (Singh et al. [@CR1387], [@CR1388], [@CR1389], [@CR1391], [@CR1393]) have now demonstrated, which is that the 'something else' (Kell [@CR766], [@CR767]) is (as so often) an imbalance in iron metabolism. They start by showing (Singh et al. [@CR1389]) that even normal PrP^C^ mediates cellular iron uptake and transport and that mutant PrP forms alter cellular iron levels differentially.

PrP^C^ binds iron tightly, and this helps effect its conversion to PrP^Sc^ (Singh et al. [@CR1391], [@CR1393]). Singh et al. ([@CR1387]) showed that PrP^Sc^ can sequester cellular iron in insoluble PrP^Sc^--ferritin complexes, making it bio-unavailable, and that this leads to an upregulation of iron uptake via transferrin and its receptor, leading to an overall iron excess in brain tissue. This was true for both scrapie and sporadic Creutzfeldt--Jakob disease, and stresses that it is not only the total amount of Fe(II) and Fe(III) that matter but their*speciation*. Mice knocked out for PrP also show derangement in iron metabolism (Singh et al. [@CR1388]), and given what we know already (Kell [@CR766]) this leads to many obvious predictions of other diseases (Altamura and Muckenthaler [@CR39]; Granic et al. [@CR549]; Reddy et al. [@CR1262]; Serra et al. [@CR1365]) to which they might be susceptible. It has not yet been shown that PrP^Sc^--ferritin complexes catalyse OH^•^ production directly, but if this is increased in diseased brains this continuous,*autocatalytic* spewing out of toxic OH^•^ radicals would clearly be able to account for the massive damage observed. A systems biology approach by Hwang et al. (Hwang et al. [@CR662]) also found many genes of iron metabolism modified in prion disease. There is little doubt that all these new findings about the role of iron (and other metals, e.g. Brown et al. [@CR197]) open up many new inroads into understanding the important role of iron in prion diseases, and thereby novel therapeutic options involving both anti-oxidants and cell-permeable iron chelators. Some of these new ideas and findings are illustrated in Fig. [5](#Fig5){ref-type="fig"}.

Finally, here, it is worth pointing up the evidence for the role of iron and its metabolic dysregulation in the oxidative stress-mediated aetiology of scrapie (Choi et al. [@CR276]; Fernaeus et al. [@CR420]; Fernaeus and Land [@CR423]; Gudmundsdóttir et al. [@CR560]; Kim et al. [@CR795], [@CR791]; Pamplona et al. [@CR1149]; Singh et al. [@CR1387], [@CR1391], [@CR1393]; Wong et al. [@CR1628], [@CR1629]; Yun et al.[@CR1674]), a prion disease of sheep and goats (Bulgin and Melson [@CR206]; Hur et al. [@CR660]) and of CJD (Choi et al. [@CR276]; Freixes et al.[@CR356]; Petersen et al. [@CR1193]; Singh et al. [@CR1387], [@CR1391], [@CR1393]). As such, the use of geostatistics relating the variation of metals present in soils to prion disease prevalence is also a powerful tool here (e.g. Gudmundsdóttir et al. [@CR563]; Imrie et al. [@CR665]; Purdey [@CR1230]; Stevens et al.[@CR1432]).

Iron deposition and disease: cause or effect? The case of atherosclerosis {#Sec12}
=========================================================================

I have implied that the role of unliganded iron is*causative* of a variety of sequelae, but sometimes this is hard to infer as the networks in which iron is involved are multiple and complex (hence the need for a systems approach---see later), and often simple one-time snapshots of covariates do not permit the inference of causality. However, one effect of the reaction of hydroxyl radicals (their formation catalysed by unliganded iron) with proteins (or lipids) is to tend to make those proteins (or lipids) insoluble or fibrotic (Davies [@CR344]; Fig. [6](#Fig6){ref-type="fig"}), and if one believes that this*is* causative, the presence of insoluble plaques should correlate with the presence of the iron that is seen to have caused their formation and thereby became entrapped (and may yet be further reactive). Because of its biomedical importance, considerable work has been performed on atherosclerotic lesions, which provide a very clear example.

Atherosclerosis is a progressive (and inflammatory[)]{.ul} disease (Altman [@CR41]; Binder et al. [@CR150]; Blake and Ridker [@CR158]; Duewell et al. [@CR384]; Dwyer et al. [@CR392]; Forrester [@CR443], [@CR444]; Gieseg et al. [@CR511]; Grainger [@CR551]; Hansson [@CR597], [@CR598]; Himmelfarb et al. [@CR628]; Kibel et al. [@CR786]; Kunsch and Medford [@CR850]; Libby [@CR911]; Libby et al. [@CR910]; Madamanchi et al. [@CR963], [@CR964]; Mullenix et al. [@CR1070]; Nigro et al. [@CR1101]; Packard and Libby [@CR1145]; Paoletti et al. [@CR1143]; Popa et al. [@CR1199]; Rader and Daugherty [@CR1241]; Ridker et al.et al. [@CR1265]; Ross [@CR1302]; Schleicher and Friess [@CR1342]; Subramanian and Ferrante [@CR1444]; Sullivan [@CR1468]; Tan and Lip [@CR1486]; Tang et al. [@CR1490]; Taqueti et al. [@CR1478]; Tedgui and Mallat [@CR1493]; van Leuven et al. [@CR1551]; van Oostrom et al. [@CR1539]; Willerson and Ridker [@CR1629]; Young et al. [@CR1669]) characterized by the accumulation of both oxidised lipids and various fibrous elements in arteries, often as plaques (Lusis [@CR957]; Stocker and Keaney [@CR1447]). Several lines of evidence point to the involvement of iron in these processes:Both iron and oxidised lipids (de Valk and Marx [@CR349]; Smith et al. [@CR1401]) are found in atherosclerotic lesions (Altamura and Muckenthaler [@CR39]; Brewer [@CR189]; Chau [@CR263]; Fernandes de Godoy et al. [@CR1424]; Gajda et al. [@CR472]; Halliwell [@CR588]; Horwitz et al. [@CR647]; Kazi et al. [@CR758]; Lee et al. [@CR877]; McRae et al. [@CR1018]; Rajendran et al. [@CR1244]; Ramakrishna et al. [@CR1235]; Roijers et al. [@CR1292]; Smith et al. [@CR1414]; Stadler et al. [@CR1425]; Stanley et al. [@CR1428]; Stocker and Keaney [@CR1448]; Sullivan [@CR1468]; Watt et al. [@CR1588]; Wolff et al. [@CR1637]; Yuan and Li [@CR1683])Iron depletion by dietary or other means delays the formation of such lesions (Ferrara and Taylor [@CR430]; Halliwell [@CR588]; Lee et al. [@CR885]; Matthews et al. [@CR1008]; Ponraj et al. [@CR1199]; Ren et al. [@CR1267]).There is a correlation between iron status and atherosclerosis (Ahluwalia et al. [@CR23]; Chau [@CR263]; Day et al. [@CR345]; de Valk and Marx [@CR349]; DePalma et al. [@CR357]; Gozzelino et al. [@CR543]; Howes et al. [@CR646]; Kallianpur [@CR726]; Kartikasari et al. [@CR744]; Kiechl et al. [@CR790]; Lapenna et al. [@CR865]; Marx et al. [@CR1000]; McRae et al. [@CR1021]; Minqin et al. 2003; Ramakrishna et al. [@CR1247]; Ren et al. [@CR1255]; Salonen et al. [@CR1316]; Shah and Alam [@CR1366]; Sullivan [@CR1466], [@CR1468]; You et al. [@CR1676]; You and Wang [@CR1677]; Zacharski et al. [@CR1688]; Zacharski and Gerhard [@CR1690]) (and zinc is protective only against subsequent calcification, Stadler et al. [@CR1438])Exogenous ferric iron is deleterious to endothelial function (Rooyakkers et al. [@CR1297])Iron chelation improves endothelial function (Altamura and Muckenthaler [@CR39]; Duffy et al. [@CR385]; Halliwell [@CR588]; Ishizaka et al. [@CR675]; Saito et al. [@CR1311]; Thomas et al. [@CR1498]).Iron levels in plaques correlate with the amount of oxidised proteins therein (Stanley et al. [@CR1440]); indeed in one study (Stadler et al. [@CR1437]), the EPR-detectable iron (essentially Fe(III)) in atherosclerotic tissue was*seventeen times greater* than that in the equivalent healthy tissue. I redraw these data in Fig. [7](#Fig7){ref-type="fig"}.

It seems clear that the application of similar studies to other diseases in which plaque formation occurs will be of benefit. Indeed, the location of iron in plaques has also been observed, for instance, for Alzheimer's (e.g. Collingwood et al. [@CR296]; Connor et al. [@CR300]; El Tannir El Tayara et al. [@CR396]; Ghribi et al. [@CR507]; Haacke et al. [@CR574]; Lovell et al. [@CR948]; Morgan et al. [@CR1061]; Quintana [@CR1235]; Quintana et al. [@CR1236]; Sayre et al. [@CR1323]; Schrag et al. [@CR1347]), ALS (Leveugle et al. [@CR899]), MS (Haacke et al. [@CR576]) and Parkinson's (see above).

Sepsis, septic shock and the systemic inflammatory response syndrome {#Sec13}
====================================================================

Although prions lack nucleic acids, they are seen as infectious agents. Bacteria are more conventional infective agents, and bacterial sepsis provides a very interesting example in which iron release is the key to cell death and the multiple organ failure that normally precedes organismal death. This said, the processes leading to septic shock and ultimately death (Fig. [8](#Fig8){ref-type="fig"}) are independent of the presence of viable/culturable bacteria (as defined in Kaprelyants et al. [@CR736]; Kell et al. [@CR771]), i.e. in the apparent absence of infection (Goris [@CR540]; Suntharalingam et al. [@CR1472]). This is because it is the*products* of bacteria, especially lipopolysaccharide (LPS), that cause the cells themselves to initiate the progressive processes of self-destruction. The sequelae are typically referred to as a systemic inflammatory response syndrome (SIRS) (e.g. Baue et al. [@CR112]; Beal and Cerra [@CR116]; Bolton [@CR166]; Bone [@CR168]; Davies and Hagen [@CR343]; Gutteridge and Mitchell [@CR571]; Hotchkiss and Karl [@CR648]; Johnson and Mayers [@CR707]; Keel and Trentz [@CR760]; Leithead et al. [@CR894]; Lolis and Bucala [@CR938]; Martin et al. [@CR996]; Nguyen et al. [@CR1100]; Protti and Singer [@CR1224]; Rittirsch et al. [@CR1273]; Ulloa et al. [@CR1521]).

It is by now well established that---while a 'cytokine storm' (Huang et al. [@CR654]; Sriskandan and Altmann [@CR1435]; Stacey et al. [@CR1436]; Suntharalingam et al. [@CR1472]; Wang and Ma [@CR1584]; Woo et al. [@CR1645]) is an important part of the aetiology of sepsis/septic shock---these phenomena are associated with the hyperproduction of ROSs (Abdelrahman et al. [@CR2]; Andrades et al. [@CR52]; Bulger and Maier [@CR205]; Cadenas and Cadenas [@CR220]; Closa and Folch-Puy [@CR291]; Crimi et al. [@CR320], [@CR321]; Goode and Webster [@CR534]; Gutteridge and Mitchell [@CR571]; Horn [@CR644]; Javadi et al. [@CR688]; Lagan et al. [@CR858]; Lemineur et al. [@CR894]; Mishra [@CR1052]; Protti and Singer [@CR1224]; Quinlan et al. [@CR1220]; Redl et al. [@CR1251]; Victor et al. [@CR1552], [@CR1553]; Vlessis et al. [@CR1560]), and (local and circulating) free iron is raised in sepsis and related conditions (Duvigneau et al. [@CR388]; Galley et al. [@CR477], [@CR478]; Galley and Webster [@CR481]; Ghio et al. [@CR505]; Lagan et al. [@CR859]), as is the iron siderophore-binding protein lipocalin-2 (Hattori et al. [@CR606]).

The natural iron-chelating antioxidant melatonin has been found to be particularly effective in preventing septic shock (Carrillo-Vico et al. [@CR239]; Escames et al. [@CR401]; Reynolds et al. [@CR1270]), and a variety of suitable antioxidants have shown promise (Bekyarova et al. [@CR128]; Cuzzocrea et al. [@CR329], [@CR330]; Di Paola et al. [@CR364]; Galley et al. [@CR480]; Mishra [@CR1052]; Nathens et al. [@CR1088]; Sebai et al. [@CR1344]; Streck et al. [@CR1443]; Zapelini et al. [@CR1695]). Most importantly, antioxidants are especially effective when given in combination with iron chelators (Barichello et al. [@CR100]; Ritter et al. [@CR1283], [@CR1284]) (see also Bulucu et al. [@CR208]; Cassol et al. [@CR241]; Petronilho et al. [@CR1195]; Pinho et al. [@CR1204]; Teixeira et al. [@CR1494]; Valvassori et al. [@CR1548]). Erythropoietin is also protective (Abdelrahman et al. [@CR3]; Cuzzocrea et al. [@CR329]), as is the iron-binder lactoferrin (Tian et al. [@CR1501]) and as are anti-inflammatory statins (Durant et al. [@CR387]; Gao et al. [@CR484]; Kopterides and Falagas [@CR827]). All of these observations make it very clear indeed that iron is intimately involved in the death following SIRS and sepsis, and---while not even mentioned in the guidelines (Dellinger et al. [@CR353])---that its effective chelation should be considered for research leading towards its inclusion as an important part of any therapy.

Bactericidal antibiotics {#Sec14}
========================

The classical test for if a bacterium is (or was) 'alive' is to analyze its ability to multiply, i.e. viability = culturability (Kell et al. [@CR773]; Postgate [@CR1218], [@CR1219]). Accordingly, bacterial antibiotics have long been classified into those that are bacteriostatic, i.e. stop individual cells growing but allow culturability to recover if the antibiotic is removed, and those that are bactericidal, i.e. that actually kill cells and thereby decrease the numbers of those that*are* culturable (capable of multiplication) even if the antibiotic is removed. Since this clearly implies that causing growth to cease is not of itself bactericidal, and anyway different antibiotics have a variety of different modes of action, it has always been a slight mystery as to what it is that makes a particular antibiotic bactericidal rather than merely bacteriostatic.

A very important paper (Kohanski et al. [@CR814]) provides much of the answer. As one may suppose from the subject matter of this review, iron is again involved, specifically via the Fenton reaction in which poorly liganded ferrous ions reduce the comparatively harmless hydrogen peroxide to the deadly hydroxyl radical.

Based on a previous paper from the same group (Dwyer et al. [@CR389]), Kohanski et al. ([@CR815]) (see also Davies et al. [@CR342]; Dwyer et al. [@CR391], [@CR388]; Imlay [@CR667]; Kohanski et al. [@CR815]; Liu et al.[@CR926]; Wang and Zhao, [@CR1593]) reported that the three major classes of bactericidal antibiotics (exemplified by norfloxacin, ampicillin and kanamycin), regardless of drug--target interaction, utilize internal iron liberated from iron--sulphur clusters to promote Fenton-mediated hydroxyl radical formation in bacteria, that such hydroxyl radical generation contributes to the killing efficiency of these lethal drugs (probably via their known ability to damage DNA), and that in contrast antibiotics that are merely bacteriostatic do not cause the production of such hydroxyl radicals. The availability of multiple genetically marked strains allowed several predictions (such as the resistance to be expected in mutants that could not make iron-sulphur centres so effectively) to be tested successfully. Nitric oxide is correspondingly protective (Gusarov et al. [@CR565]). This suggests, much as above, that there is a common mechanism of iron/hydroxyl-mediated cellular death underlying the action of all classes of bactericidal antibiotics and opens up many new possibilities for combination therapies based on promoting this kind of activity selectively (see Fig. [9](#Fig9){ref-type="fig"}). This said, how synergistic a combination is does depend on the exact speciation of the liganded iron; surprisingly, the iron chelator deferasirox *promoted* the antibacterial activity of ciprofloxacin against *V. vulnificus* (Neupane and Kim [@CR1099]), as did deferiprone with various azoles against *Aspergillus fumigatus*, while deferoxamine was antagonistic to azoles (Zarember et al. [@CR1684]). As with any complex system, the interactions can be highly dosedependent (Hegreness et al. [@CR615]; Kohanski et al. [@CR297]; Yeh et al. [@CR1656]).

Viruses {#Sec15}
=======

A typical viral infection involves the biding of virus to the cell surface followed by internalisation and other effects. Some viruses are especially virulent, and as well as inflammation cause the death of cells that they have invaded. It is obviously of interest to establish whether iron is involved in this kind of cell death (and if so whether iron chelation might contribute to a suitable therapy during the acute phase of an infection).

The above suggestions are certainly true of infections caused by **influenza A** (Visseren et al. [@CR1567]) (see also Akaike et al. [@CR25]; Beck et al. [@CR116]), **herpes simplex virus** (Gennero et al. [@CR497]; Lamey and Biagioni [@CR862]; Romeo et al. [@CR1283]), **hepatitis C** (Alavian and Tabatabaei [@CR30]; Alla and Bonkovsky [@CR35]; Ameli et al. [@CR43]; Bassett [@CR109]; Batts [@CR111]; Bonkovsky [@CR170]; Bonkovsky et al. [@CR171]; Desai et al. 2008; Di Marco et al. [@CR363]; Drakesmith and Prentice [@CR379]; Fargion et al. [@CR412]; Ferrara et al. [@CR431]; Franchini et al. [@CR448]; Fujita et al. [@CR464], [@CR465]; Fujita and Takei [@CR468]; Girelli et al. [@CR514]; Gürkan et al. [@CR564]; Guyader et al. [@CR572]; Hayashi and Yano [@CR610]; Heathcote [@CR615]; Kaito [@CR722]; Kaito et al. [@CR723]; Kato et al. [@CR746], [@CR747]; Ko et al. [@CR810]; Mahmoud et al. [@CR970]; Mueller et al. [@CR1069]; Nahon et al. [@CR1082]; Nishina et al. [@CR1107]; Otogawa et al. [@CR1142]; Price and Kowdley [@CR1221]; Rigamonti et al. [@CR1280]; Sebastiani and Walker [@CR1357]; Sikorska et al. [@CR1379]; Sugimoto et al. [@CR1460]; Tanaka et al. [@CR1487]; Tanaka and Kiyosawa [@CR1489]; Trinder et al. [@CR1514]; Tung et al. [@CR1529]; Valenti et al. [@CR1531]; Venturini et al. [@CR1561]; Won et al. [@CR1639]) and **HIV** (Boelaert et al. [@CR162]; Butensky James et al. [@CR216]; de Monyé et al. [@CR346]; Debebe et al. [@CR351]; Drakesmith and Prentice [@CR379]; Georgiou et al. [@CR498]; Gordeuk et al. [@CR536], [@CR539]; Kagu et al. [@CR718]; Ketonen et al. [@CR781]; McDermid et al. [@CR1015]; McDermid and Prentice [@CR1016]; McDermid et al. [@CR1017]; Meyer [@CR1032]; Northrop-Clewes [@CR1111]; Rawat et al. [@CR1257]; Savarino et al. [@CR1318]; Schreck et al. [@CR1339]; Szajerka and Jablecki [@CR1480]; Traoré and Meyer [@CR1524], [@CR1525]; van Asbeck et al. [@CR1549]; Weinberg [@CR136]; Ziegler et al. [@CR1703]).

Microbial, plant and animal toxins {#Sec16}
==================================

Before considering chemical toxicants, it is worth noting that the natural world contains a very great many molecules that are toxic to cells and hence organisms. Although the mechanisms of cell death are rather rarely pursued, there is evidence for the involvement of iron in the sequelae of exposure to toxic doses of gentamicin (Petronilho et al. [@CR1195]), ochratoxin (Hasinoff et al. [@CR600]; Omar et al. [@CR1123]; Størmer and Hoiby [@CR1454]) and ricin (Hassoun and Wang [@CR604]; Kumar et al. [@CR846]; Muldoon et al. [@CR1070]), as well as to certain snake venoms (Gutierrez et al. [@CR570]).

Chemical toxicants: aniline, asbestos, dioxins, hydrazines, methyl mercury and paraquat {#Sec17}
=======================================================================================

The most dangerous kinds of man-made toxic chemical agents, those that kill cells or organisms, exhibit a rich diversity of chemical structures and can bind to multiple cellular targets, to the extent that a unitary mode of action is not considered likely. (This said, the same was thought to be true for the mode of action of general anaesthetics or narcotics, and they turn out to have a comparatively small number of rather specific protein targets (Dobson et al. [@CR367]; Dobson and Kell [@CR370]; Franks [@CR456], [@CR457]; Grasshoff et al. [@CR551])). However, this does not mean that multiple initial events do not at some point converge to a comparatively small number of crucial events of cell death (whether through necrosis or apoptosis, Vanden Berghe et al. [@CR1554]), equivalent to the 'bow-tie' model of cellular networks (see e.g. Csete and Doyle [@CR325]; Ma'ayan [@CR959]; Ma et al. [@CR961], [@CR960]; Ma and Zeng [@CR962]; Oda and Kitano [@CR1124]; Rodríguez-Caso et al. [@CR1278]; Wang and Chen [@CR1595]; Zhao et al. [@CR1698], [@CR1709]) and (Fig. [10](#Fig10){ref-type="fig"}), and my purpose here is to highlight the evidence that iron-based mechanisms, largely based on Fenton chemistry, are involved in a number of these cases. A recent special issue on toxicants and neurodegeneration is also of interest here (Gupta and Milatovic [@CR566]).

Acetaminophen {#Sec18}
-------------

Acetaminophen (paracetamol in the United Kingdom) ([ChEBI 46195](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:46195)) is a well-known analgesic that is nevertheless highly toxic at concentrations in excess of the therapeutic dose, as it is converted to the electrophilic N-acetyl-p-benzoquinone imine (NAPQI). If glutathione is in insufficient supply, the NAPQI cannot be conjugated harmlessly by glutathione and so it reacts covalently with proteins, especially mitochondrial proteins (Hinson et al. [@CR630]; Jaeschke and Bajt [@CR681]; Kon et al. [@CR820]; Masubuchi et al. [@CR1004]; Reid et al. [@CR1252]), resulting in apoptotic cell death and organismal death via liver damage (e.g. Barker et al. [@CR100]; Beckett et al. [@CR122]; James et al. [@CR679]; Martin-Murphy et al. [@CR995]; Olaleye and Rocha [@CR1131]). One of the effects of mitochondrial damage is iron release, and it has long been known that iron chelators help prevent this toxicity (Sakaida et al. [@CR1312]; Schnellmann et al. [@CR1334]). Appropriate hydroxyl radical scavengers are also partly protective (Chandrasekaran et al. [@CR257]), while lactoferrin is also protective, although not apparently only via its iron-binding capacity (Yin et al. [@CR1669]).

Aniline {#Sec19}
-------

As is well known, the adulteration with aniline of cooking oil in Spain showed that aniline so administered can be exceedingly toxic to humans (the 'toxic oil syndrome', Hill et al. [@CR629]; Vázquez Roncero et al. [@CR1547]), especially in the lungs and spleen. It is now clear (Bomhard and Herbold [@CR167]; Khan et al. [@CR784], [@CR785]; Ma et al. [@CR959]; Mellert et al. [@CR1025]; Wang et al. [@CR1635], [@CR1577], [@CR1576]) that iron is heavily involved in this via Fenton chemistry.

Asbestos {#Sec20}
--------

Many mutagens are carcinogens, typically by intercalating into DNA, so it was not a priori obvious why asbestos fibres---enormously larger than the diameter of DNA---should be so toxic. The mystery was solved when it was realised that asbestos does in fact contain and bind iron, that the sharp surface of the iron-loaded fibres can catalyse hydroxyl radical formation and that it is*this* that provides the toxic mechanism (Aljandali et al. [@CR34]; Burrows and Muller [@CR209]; Chao et al. [@CR259]; Chen et al. [@CR266]; Dai and Churg [@CR336]; Fubini and Arean [@CR461]; Gilmour et al. [@CR513]; Governa et al. [@CR545]; Gulumian and van Wyk [@CR564]; Hardy and Aust [@CR600], [@CR601]; Hippeli and Elstner [@CR635]; Jaurand [@CR686]; Kamp et al. [@CR727]; Kamp and Weitzman [@CR733], [@CR734]; Kelleher et al. [@CR778]; Levresse et al. [@CR901]; Lund and Aust [@CR955], [@CR956]; Mossman and Churg [@CR1068]; Mossman et al. [@CR1069]; Park and Aust [@CR1162]; Quinlan et al. [@CR1222]; Shatos et al. [@CR1362]; Shen et al. [@CR1366]; Weinberg [@CR1606]; Weitzman and Graceffa [@CR1616]; Xu et al. [@CR1640]; Azad et al. [@CR77]; Bhattacharya et al. [@CR146]; Daghino et al. [@CR335]; Fantauzzi et al. [@CR411]; Fattman et al. [@CR414]; Gazzano et al. [@CR492]; Ghio et al. [@CR504], [@CR502]; Heintz et al. [@CR617]; Kamp [@CR728]; Knaapen et al. [@CR805]; Liu et al. [@CR922]; Nymark et al. [@CR1113]; Panduri et al. [@CR1154]; Poser et al. [@CR1217]; Quinlan et al. [@CR1221]; Shannahan et al.; Shukla et al. [@CR1375], [@CR1376]; Sørensen et al. [@CR1426]; Toyokuni [@CR1519], [@CR1520]; Upadhyay and Kamp [@CR1536]; Valavanidis et al. [@CR1540]).

Dioxins {#Sec21}
-------

Dioxins are formed typically via the thermal combustion of halogen-containing compounds, and a chief product, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD, often referred to simply as 'dioxin' ([ChEBI 28119](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28119)), notoriously produced during the 1976 Seveso chemical plant explosion and as an impurity in Agent Orange (a roughly 1:1 mixture of the plant hormone (auxin---[ChEBI 22676](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:22676)) analogues) 2,4-dichlorophenoxyacetic acid (2,4-D; [ChEBI 28854](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28854)) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T; [ChEBI 27903](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27903)), is both a cause of chloracne and is a hepato-carcinogen. It was found that mice low in iron are resistant to this hepatotoxicity however (Poland and Knutson [@CR1208]; Sweeny et al. [@CR1464]), strongly implicating iron. In addition, iron enhances the toxicity of dioxin (Al-Turk et al. [@CR28]; Smith et al. [@CR1412]) while iron chelators reduce it (Al-Bayati and Stohs [@CR27]; Wahba et al. [@CR1565]). While the exact details have still not been worked out, there is little doubt that iron is important in the toxicity of a wide variety of polyhalogenated aromatics (Smith and Chernova [@CR1411]; Smith and Elder [@CR1413]), including hexachlorobenzene ([ChEBI 5692](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:5692)) (Franklin et al. [@CR453]).

Hydrazines {#Sec22}
----------

Phenylhydrazine ([ChEBI 27924](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27924)) (like other hydrazines) is a reactive substance that is commonly used in toxicity studies. It is known (Agrawal et al. [@CR16]; Atanasova et al. [@CR69]; Ferrali et al. [@CR426], [@CR427]; Fraenkel et al. [@CR449]; Karbownik et al. [@CR737]; Kim et al. [@CR796]; Latunde-Dada et al.[@CR865]; Rokushima et al.[@CR1281], [@CR1282]; Sharma and Haldar [@CR1372]; Yamamoto and Kawanishi [@CR1660]) to induce haemolytic anaemia and iron release and thence cytotoxicity. Melatonin can be protective (Sharma and Haldar [@CR1372]).

Methyl mercury {#Sec23}
--------------

Originally highlighted via 'Minamata disease' (a prominent symptom of which, as with many neurological disease, is ataxia), methylmercury ([ChEBI 30785](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:30785)) is a well-known neurotoxicant (Clarkson et al. [@CR288]). Like most if not all other xenobiotics (Dobson et al. [@CR367]; Dobson and Kell [@CR370]; Dobson et al. [@CR369]; Kell and Dobson [@CR771]), it requires one or more carriers for cellular uptake---in this case, when complexed to L-cysteine, the 'large amino acid' transporter (Kanai and Endou [@CR735]; Simmons-Willis et al.[@CR1385]; Yin et al. [@CR1671]). There is certainly evidence that exposure to this agent causes oxidative stress (Ali et al.[@CR32]; Aschner et al. [@CR63]; Atchison and Hare [@CR70]; Franco et al. [@CR449]; Johansson et al. [@CR706]; Sanfeliu et al. [@CR1311]; Sarafian et al. [@CR1315]; Yee and Choi [@CR1665], [@CR1666]; Yin et al. [@CR1670]) and raises cellular iron levels (Ilbäck et al. [@CR661]) and that anti-oxidants (Daré et al. [@CR337]; Kaur et al. [@CR751]; Sarafian and Verity [@CR1326]; Shanker and Aschner [@CR1369]; Usuki et al. [@CR1538]; Watanabe et al. [@CR1599]; Yamashita et al. [@CR1661]; Zurich and Monnet-Tschudi [@CR1721]), metallothioneins (West et al. [@CR751]) and/or iron chelators (Castoldi et al. [@CR244]; LeBel et al. [@CR870]; Sarafian and Verity [@CR1326]; Stohs and Bagchi [@CR1449]) can be protective. Taken together, this does imply strongly a role for iron-mediated cytotoxicity of the type highlighted herein in the pathogenesis of methylmercury poisoning.

Paraquat {#Sec24}
--------

Paraquat (N,N′-dimethyl-4,4′-bipyridinium dichloride; [ChEBI 34905](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:34905)) is a well-known herbicide and toxicant, whose mode of action relies on the generation of superoxide radicals. As such, its toxicity may be expected to be exacerbated by iron, and this is the case (Andersen [@CR48]; Ayaki et al. [@CR75]; Fernandez et al. [@CR425]; Peng et al. [@CR1165], [@CR1166]). In addition, again as expected from the above (and consistent with its structural similarity to the Parkinson-inducing agent MPTP-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, [ChEBI 17963](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17963)), it can induce Parkinson-like symptoms (Kaur et al. [@CR748]; Miller et al. [@CR1041]; Ossowska et al. [@CR1139]; Peng et al. [@CR1177], [@CR1178]). The protection by molecules---such as ferritin (Kaur et al. [@CR750]) and polyphenols (Jimenez-Del-Rio et al. [@CR703])---capable of chelating iron harmlessly is thus of considerable interest.

Other toxicants in which iron release has been implicated as part of the mechanisms of their toxicity {#Sec25}
-----------------------------------------------------------------------------------------------------

The list of known and potential toxicants is limitless, and part of the role of this review is to alert domain experts to the likelihood that iron, and dysregulation in iron metabolism, may mediate the toxicity of such molecules (and thus that its chelation may be important, under both acute and chronic conditions, in assisting resolution of the toxicity). To this end, I note the role of iron-induced oxidative stress in the toxicity of anthracyclines (including adriamycin/doxorubicin [ChEBI 28748](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:28748)) (Ceyssens et al. [@CR254]; Kaiserová et al. [@CR719]; Kotamraju et al. [@CR833], [@CR834]; Luft [@CR952]; Othman et al. [@CR1129]; Šimůnek et al. [@CR1399]; Thougaard et al. [@CR1512]; Xu et al. [@CR1644]), arsenic (De Vizcaya-Ruiz et al. [@CR348]; Fujihara et al. [@CR463]), beer brewed in cast iron pots (Kew and Asare [@CR784]), bleomycin ([ChEBI 3139](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3139)) (Wu et al. [@CR1636]; Yang et al. [@CR1662]), C60 fullerenes (Usenko et al. [@CR1525]), carbon nanotubes (Murray et al. [@CR1078]) (and see Guo et al. [@CR565]; Jurkschat et al. [@CR714]), carbon tetrachloride (Mansour [@CR992]; Ogeturk et al. [@CR1125]), organophosphates (Goel et al. [@CR516]), sulphur mustard agents (Korkmaz et al. [@CR829]; Korkmaz et al. [@CR830]; Naghii [@CR1081]) and talc nanoparticles (Akhtar et al. [@CR26]). Welding fumes are toxic and contain both iron and manganese (Flynn and Susi [@CR440]; Sriram et al. [@CR1434]), and the toxicity of nano-iron itself has also been studied (Li et al. [@CR906]).

Apoptosis or necrosis? {#Sec26}
======================

As is well known, cells can die by both necrosis and by a more regulated form, apoptosis. While this---nor 'normal' ageing (summarised e.g. by Bishop et al. [@CR154]b; Finkel [@CR438]; Franco et al. [@CR452]; Gems [@CR494]; Kenyon [@CR781]; Kirkwood [@CR800]; Muller et al. [@CR1072]; Vaupel [@CR1556]), in which various degradative processes including iron dysregulation can be implicated (e.g. Brewer [@CR190]; Cass et al. [@CR241]; Cook and Yu [@CR302]; Facchini [@CR406]; Galaris et al. [@CR475]; Kell [@CR766]; Kujoth et al. [@CR846]; Kurz et al. [@CR855]; Massie et al. [@CR1003]; Napoli et al. [@CR1086]; Pfefferbaum et al. [@CR1468]; Terman et al. [@CR1490]; Xu et al. [@CR1653])---is not the focus of this review, it is reasonable to enquire as to what kind of evidence exists for the mechanism(s) of cell death contingent upon iron dysregulation. As it turns out, while there is a little evidence that iron overload can cause necrosis (Babatasi et al. [@CR81]; Traoré and Meyer [@CR1525]; Vanden Berghe et al. [@CR1554]; Vanlangenakker et al. [@CR1543]), there is abundant evidence for the ability of iron to cause apoptosis (Kotamraju et al. [@CR834], [@CR835]; Kurz et al. [@CR852], [@CR855]; Vanden Berghe et al. [@CR1554]), and---depending presumably on the exact liganding of the iron (Kell[@CR766])---this can be effected when iron is ostensibly depleted (e.g. Bergman et al. [@CR142]; Bidle and Bender [@CR149]; Brard et al. [@CR181]; Buss et al. [@CR213]; Fukuchi et al. [@CR467]; Greene et al. [@CR557]; Haq et al. [@CR596]; Hileti et al. [@CR625]; Jiang et al. [@CR698]; Jin et al. [@CR702]; Koc et al. [@CR811]; Kovář et al. [@CR839], [@CR839]; Leardi et al. [@CR870]; Lee et al. [@CR883], [@CR884]; Pan et al. [@CR1138]; Simonart et al. [@CR1398]; Sun et al. [@CR1459]; Truksa et al. [@CR1527]; Zhang et al. [@CR1707]; Zhao et al. [@CR1712]) or in excess (e.g. Aljandali et al. [@CR34]; Cozzi et al. [@CR315], [@CR316]; Devireddy et al. [@CR360]; Franke et al. [@CR454]; Jacob et al. [@CR678], [@CR679]; Javadi et al. [@CR687]; Jímenez Del Río and Vélez-Pardo [@CR704]; Kamp et al. [@CR730]; Kawabata et al. [@CR754]; Kermer et al. [@CR782]; Kooncumchoo et al. [@CR824]; Kruman et al. [@CR842]; Kummer et al. [@CR849]; Kurz et al. [@CR853], [@CR855]; Lakshmi Devi and Anuradha [@CR860]; Lee et al. [@CR883]; Levenson [@CR898]; Lu et al. [@CR950]; Ma et al. [@CR961]; Messer et al. [@CR1027]; Murakami et al. [@CR1076]; Natoli et al. [@CR906]; Persson [@CR1190]; Polla et al. [@CR1197]; Schlawe et al. [@CR1341]; Shin and Kim [@CR1382]; Shukla et al. [@CR1376]; Tenopoulou et al. [@CR1483]; Upadhyay and Kamp [@CR1536]; Vélez-Pardo et al. [@CR1548]; Zhao et al. [@CR1699]).

Inflammation and NF-κB {#Sec27}
======================

As reviewed in the previous survey (Kell [@CR766]) and elsewhere (e.g. Shoelson and Goldfine [@CR1384]; Shoelson et al.[@CR1373]), inflammation lies at the heart of many of these processes, and pathways involving NF-κB (see e.g. <http://www.nf-kb.org/>) are especially core here (e.g. Ali and Mann [@CR31]; Circu and Aw [@CR287]; Granic et al. [@CR552]; Karin [@CR740]; Karin and Greten [@CR741]; Li et al.[@CR906]; Maeda and Omata [@CR968]; Simmonds and Foxwell [@CR1396]; Zhang and Rigas [@CR1706]). Of particular relevance in ROS/iron metabolism are the facts that **NF-κB is redox-sensitive** (e.g. Aggarwal and Sung [@CR14]; Baeuerle and Henkel [@CR84]; Chandrasekaran and Taylor [@CR257]; Cho et al. [@CR272]; Dröge [@CR382]; Fulda et al. [@CR468]; Galaris et al. [@CR476]; Gloire et al. [@CR514]; Gloire and Piette [@CR518]; Ha et al. [@CR573]; Haddad et al. [@CR576]; Hayashi et al. [@CR608]; Janssen-Heininger et al. [@CR684]; Lagan et al. [@CR859]; Lukosz et al. [@CR953]; Nishi et al. [@CR1106]; Phillips et al. [@CR1187]; Schreck et al. [@CR1340], [@CR1337]; Schreck and Baeuerle [@CR1350]; Sen and Packer [@CR1363]; She et al. [@CR1376]; Surh et al. [@CR1461]; Surh and Na [@CR1474]; Thannickal and Fanburg [@CR1503]; Trachootham et al. [@CR1511], [@CR1510]; Valko et al. [@CR810]; Weinberg and Chandel [@CR1608]; Wondrak [@CR1640]; Xiong et al. [@CR1651]) and that there are links between NF-κB and NGAL/lcn2 (Bu et al. [@CR201]; Cowland et al. [@CR312], [@CR311], [@CR663]; Karlsen et al. [@CR741]) and/or hepcidin (Sow et al. [@CR1428]; Tacchini et al. [@CR1470]). Specificity is likely to come, in part, via the frequency encoding of NF-κB activity (Ashall et al. [@CR64]; Nelson et al. [@CR1095]).

Catalytic behaviour of polypeptides and proteins {#Sec28}
================================================

I have mentioned several times the idea that different proteins can bind unliganded iron to catalyse the production of hydroxyl radical, and it is certainly the case that the degree of liganding can affect these kinds of activities (Kell [@CR766]). Here it is appropriate to highlight the abilities of polypeptides and even poly(aminoacids)---whether binding metals (or not)---to exhibit catalytic activities, e.g. poly(leucine) (Carrea et al. [@CR237]; Porter et al. [@CR1204]), and how adding metals to polypeptides to make metalloenzymes can have huge effects on their catalytic activities (Pierron et al. [@CR1201]; Pordea and Ward [@CR1214]; Turner [@CR1533]). The recent development of orthogonal ribosomes capable of incorporating novel amino acids into polypeptides (Neumann et al. [@CR1095]) opens up considerable possibilities here.

Dietary and/or pharmacological treatment of iron-mediated toxicity {#Sec29}
------------------------------------------------------------------

### Pharmaceutical {#Sec30}

Developing novel pharmaceutical agents is a costly enterprise, and many candidate drugs fall by the wayside during the development process (see e.g. Dobson et al. [@CR369]; Kola and Landis [@CR817]; Leeson and Springthorpe [@CR887]). As most recently reviewed (Agarwal [@CR11]; Berdoukas et al. [@CR135]; Bolognin et al. [@CR163]; Cappellini and Pattoneri [@CR234]; Cappellini et al. [@CR235]; Clifton et al. [@CR290]; Hider et al. [@CR624]; Kell [@CR766]; Kontoghiorghes et al. [@CR823]; Kwiatkowski [@CR856]; Mladĕnka et al. [@CR1055]; Pennell et al. [@CR1180]; Perez and Franz [@CR1183]; Richardson et al. [@CR1263] and references therein), a number of (pharmacological drug) approved iron chelators do exist and thus clearly have the potential to prove beneficial in treating diseases and the sequelae of toxin exposure whose aetiology involves poorly liganded iron via the Fenton reaction. The benefits of administration of desferrioxamine in Alzheimer's, for instance, have been known for nearly 20 years (Crapper McLachlan et al. [@CR319]), benefits since observed with other iron chelators (e.g. Amit et al. [@CR45]; Bolognin et al. [@CR163]; Bush [@CR213]; Liu et al. [@CR923], [@CR925]; Perez and Franz [@CR1183]; Smith et al. [@CR1420]; Zhang et al. [@CR1691]). The implications for this and other neurodegenerative diseases---and potentially for the more acute and even chronic effects of other toxins---are obvious. Those approved clinically include Deferoxamine (Desferal; [ChEBI 31460](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31460)), Deferiprone (Ferriprox; [PubChem CID 2972](http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2972)) and Deferasirox (Exjade; [ChEBI 49005](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49005)) (Fig. [11](#Fig11){ref-type="fig"}). Note that---unlike the other two---Deferoxamine is not orally active and must be injected, and even then may fail to cross cellular membranes to exert its action appropriately (Warkentin et al.[@CR1586]).

### Dietary or nutritional/nutraceutical {#Sec31}

In addition, many organisms make so-called 'secondary' or*natural products*, whose functions are often unclear but that clearly have evolutionary benefits for the host (Hadacek et al. [@CR274]; Kell et al. [@CR772]). As I also reviewed (Kell [@CR766]), many **iron-chelating** natural products exist in (or may be added to, Pócsi et al. [@CR1207]) foodstuffs for which no full pharmaceutical regulatory controls are required and which are classed as nutritional substances. Many are **polyphenols** ([ChEBI 26195](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:26195)) (Amic et al. [@CR44]; Arts and Hollman [@CR62]; Auclair et al. [@CR73]; Cemeli et al. [@CR253]; Cheynier [@CR270]; Geronikaki and Gavalas [@CR503]; Halliwell [@CR587]; Jovanovic and Simic [@CR713]; Kandaswami and Middleton [@CR736]; Kiokias et al. [@CR798]; Korkina and Afanas'ev [@CR828]; Linseisen and Rohrmann [@CR923]; Loke et al. [@CR937]; Manach et al. [@CR979], [@CR978], [@CR980]; Pérez-Jiménez et al. [@CR1169]; Perron and Brumaghim [@CR1188]; Perron et al. [@CR1177]; Petti and Scully [@CR1196]; Pietta [@CR1203]; Rice-Evans and Packer [@CR1262]; Scalbert et al. [@CR1324]; Scalbert and Williamson [@CR1337]; Seifried et al. [@CR1360]; Slemmer et al. [@CR1396]; Spencer et al.[@CR1419]; Yadav and Bhatnagar [@CR1657], [@CR1658], [@CR1659]), including the anthocyanins that proved chemoprotective (Butelli et al. [@CR215]) in a mouse p53 cancer model. Since the previous review (Kell [@CR766]), I would draw particular attention to a comprehensive overview of the subject (Perron and Brumaghim [@CR1188]), as well as new reviews and papers on the chief polyphenol in green tea, (−)**epigallocatechin-3-gallate** ([ChEBI 4806](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4806)) (Adhami et al. [@CR8]; Butt and Sultan [@CR217]; Hsieh et al. [@CR647]; Jimenez-Del-Rio et al. [@CR703]; Johnson et al. [@CR705]; Pandey and Gupta [@CR1151]; Paterniti et al. [@CR1169]; Ramesh et al. [@CR1248]; Reznichenko et al. [@CR1272]; Suh et al. [@CR1461]; Weinreb et al. [@CR1599]), on **curcumin** ([ChEBI 3962](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3962)) (a constituent of turmeric) (Aggarwal and Harikumar [@CR13]; Aggarwal and Sung [@CR14]; Anand et al. [@CR46]; Basile et al. [@CR108]; Epstein et al. [@CR396]; Hegde et al. [@CR617]; Iqbal et al. [@CR669]; Jiao et al. [@CR702]; Jurenka [@CR716]; Kalpravidh et al. [@CR727]; Majumdar et al. [@CR975]; Messner et al. [@CR1028]; Patil et al. [@CR1158]; Ravindran et al. [@CR1244]; Rivera-Espinoza and Muriel [@CR1287]; Thephinlap et al. [@CR1500]; Thomas et al. [@CR1497]; Tuntipopipat et al. [@CR1518]; Wang et al. [@CR1574]), on **eugenol** ([ChEBI 4917](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4917)) (Nagababu et al. [@CR1077]) (and cf. Allen and Cornforth [@CR36]), on nepetoidin caffeic acid esters (Maioli et al. [@CR905]), on **quercetin** ([ChEBI 16243](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16243)) (Chobot [@CR274]; Kitagawa et al. [@CR801]; Krukoski et al. [@CR841]; Lorrain et al. [@CR943]; Park et al. [@CR1151]; Pavlica and Gebhardt [@CR1172]; Smirnova et al. [@CR1398]; Terao [@CR1497]; Vlachodimitropoulou et al. [@CR1556]) and on **melatonin** ([CHEBI 16796](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16796)) (Borah and Mohanakumar [@CR172]; Korkmaz et al. [@CR829], [@CR830]; Reiter et al. [@CR1254]; Sener et al. [@CR1364]; Sharma and Haldar [@CR1372]; Signorini et al. [@CR1390]). Many of the protective effects observed are likely due to the iron chelating, as well as directly antioxidative (redox) properties of these molecules (e.g. Ferrali et al. [@CR426]; Hague et al. [@CR580]; Halliwell [@CR588]; Halliwell et al. [@CR587]; Hider et al. [@CR623]; Končić et al. [@CR822]; Lopes et al. [@CR939]; Mandel et al. [@CR986]; Mandel and Youdim [@CR989]; Morel et al. [@CR1061]; Nijveldt et al. [@CR1105]; Rice-Evans et al. [@CR1261]; Rice-Evans and Packer [@CR1262]; Weinreb et al. [@CR1600], [@CR1599]; Yoshino and Murakami [@CR1675]). Other molecules that are not themselves directly antioxidant, but have iron-binding characteristics, may also be of benefit. This is certainly true of **phytic acid** (phytate; myo-inositol-1,2,3,4,5,6-hexakis phosphate; [CHEBI 17401](http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17401)) (Aljandali et al. [@CR34]; Allen and Cornforth [@CR36]; Brune et al. [@CR199]; Davidsson et al. [@CR341]; Doria et al. [@CR374]; Glahn et al. [@CR513]; Graf and Eaton [@CR547], [@CR548]; Graf et al. [@CR546]; Grases et al. [@CR550]; Hallberg et al. [@CR583]; Han et al. [@CR590]; Hanson et al. [@CR596]; Hawkins et al. [@CR608]; Kamp et al. [@CR728], [@CR729], [@CR732]; Kim et al. [@CR792]; Kumar et al. [@CR119]; Minihane and Rimbach [@CR1047]; Miyamoto et al. [@CR1052]; Panduri et al. [@CR1154]; Poser et al. [@CR1217]; Rao et al. [@CR1238]; Rimbach et al. [@CR1269]; Sandberg et al. [@CR1321]; Schlemmer et al. [@CR1331]; Shamsuddin [@CR1368]; Vucenik and Shamsuddin [@CR1572]; Xu et al. [@CR1642]).

### Phlebotomy {#Sec32}

In addition, as follows implicitly from Sullivan's 'iron hypothesis' (Sullivan [@CR1462], [@CR1463], [@CR1464], [@CR1465]) (and see Kell [@CR766]), one way to decrease the amount of iron in the body is to remove it by blood-letting or phlebotomy. While phlebotomy is a very traditional nostrum, often assumed or considered to have rather dubious or at best modest scientific support, there is in fact increasing literature implying its benefits in a variety of conditions (e.g. Aigner et al. [@CR24]; Beutler [@CR144]; Broedbaek et al. [@CR193]; Brudevold et al. [@CR198]; Busca et al. [@CR210]; DePalma et al. [@CR356], [@CR357]; Dereure et al. [@CR357]; Desai et al. [@CR360]; Dwyer et al. [@CR387]; Equitani et al. [@CR399]; Facchini et al. [@CR405]; Fargion et al. [@CR412]; Fernández-Real et al. [@CR426]; Fujita et al. [@CR465]; Fujita and Takei [@CR468]; Hayashi et al. [@CR606]; Hayashi and Yano [@CR610]; Heathcote [@CR615]; Horwitz and Rosenthal [@CR646]; Hua et al. [@CR648]; Kaito [@CR722]; Kaito et al. [@CR723]; Kato et al. [@CR746], [@CR747]; Kom et al. [@CR818]; Rajpathak et al. [@CR1245]; Sullivan [@CR1468]; Sumida et al. [@CR1457]; Tanaka et al. [@CR1487], [@CR1488]; Toyokuni [@CR1520]; Zacharski et al. [@CR1689]). Plausibly such benefits are due to its role in decreasing iron stores.

Discussion: toxicology as systems biology {#Sec33}
=========================================

""When sorrows come, they come not single spies but in battalions." (Shakespeare, Hamlet.)"

It is certainly the case that reasons for the co-occurrence of two or more observables are that one causes the other or they have the same, separate cause. Since I have argued strongly here for the essentiality of iron dysregulation in a variety of syndromes (and have omitted many others, such as non-alcoholic (Baptista-Gonzalez et al. [@CR95]; Kirsch et al. [@CR800]; Kowdley [@CR841]) or alcoholic liver disease (Breitkopf et al. [@CR187]; Lecube et al. [@CR872])), and indeed cancers of various kinds (see Kell [@CR766]), the implication is that iron dysregulation can manifest in multiple different ways and that these might co-occur. There is considerable and increasing evidence for that (see e.g. Adibhatla and Hatcher [@CR9]; Baker et al. [@CR86]; Beeri et al. [@CR128]; Cole et al. [@CR292]; Franco et al. [@CR451]; Janson et al. [@CR683]; Kell [@CR766]; Li and Hölscher [@CR907]; Mascitelli et al. [@CR906]; Neumann et al. [@CR1098]; Pandolfo [@CR1152]; Roriz-Filho et al. [@CR1298]; Schnaider Beeri et al. [@CR1345]; Starley et al. [@CR1429]; Utzschneider and Kowdley [@CR1539]; Verduzco and Nathan [@CR1562]; Xu et al. [@CR1643]), with the exact outcomes being determined by different levels of expression (see for instance <http://www.proteinatlas.org/>) of different proteins in different tissues.

In a similar vein, it is not news (Attwood et al. [@CR72]; Evans [@CR402]; Hull et al. [@CR767]; Kostoff [@CR832]) that the large floods of literature have led to something of a 'balkanisation' of the literature into increasingly specialised segments, and that this makes it hard to seek to bring together such disparate parts of the literature so as to draw out general truths (Dobson and Kell [@CR370]; Kell [@CR766]), via the methods of inductive reasoning (Kell and Oliver [@CR777]; King et al. [@CR798], [@CR797]). As previously discussed, it is well established on theoretical grounds alone that the activity of any step in a biochemical network can influence the concentration of any variable (such as---fleetingly---the amount of hydroxyl radicals produced). Thus, while it is better to derive quantitative models (e.g. Coveney and Fowler [@CR310]; Csikasz-Nágy [@CR326]; Kell [@CR764], [@CR765]; Kell and Knowles [@CR775]; Kell and Westerhoff [@CR778], [@CR779]; Milo et al. [@CR1043]; Mogilner et al. [@CR1055]; Noble [@CR1108], [@CR1109], [@CR1110]; Oates et al. [@CR1110]; Phillips and Milo [@CR1200]; Tomlin and Axelrod [@CR1516]), at the very minimum one should be looking qualitatively at those factors that should be increased or decreased in order to improve the organism's ability to resist oxidative stress (Fig. [12](#Fig12){ref-type="fig"}).

Indeed, it is the very act of doing this that leads one to recognise these kinds of complex problems as problems of systems or network biology (Alon [@CR37]; Klipp et al. [@CR803]; Palsson [@CR1148]). What do I mean by this?

A systems biology view of toxicology: toxicology as systems biology {#Sec34}
-------------------------------------------------------------------

In the present case, I have adduced evidence that a range of distinct aetologies, which manifest as a variety of different syndromes or diseases, converge at some point on an autocatalytic series of reactions, involving imperfectly liganded iron, in the production of the very damaging hydroxyl radical, that by causing the destruction of appropriate cellular structures and proteins liberates further 'free' iron and other reactive oxygen species, thereby effecting positive feedback (also known as 'vicious cycles', Lin and Beal [@CR921]; Proctor and Gray [@CR1222]; Proctor et al. [@CR1211]) that leads to the production of yet further damage. The implication of this is that to be more specific we need suitable network models of the biological systems of interest (Kell [@CR766]), and of how toxicants of any kind can interact with their components.

Of course in the steady state, the amount of a substance is governed both by the processes that create it and those that decompose it (Fig. [13](#Fig13){ref-type="fig"}), and individual effects of particular substances can vary qualitatively depending on concentrations, as in hormesis (e.g. Calabrese [@CR221], [@CR222], [@CR223]; Calabrese and Baldwin [@CR225], [@CR226], [@CR227]; Calabrese and Blain [@CR228], [@CR229]; Cook and Calabrese [@CR304]; Cox [@CR314]; Gems and Partridge [@CR496]; Gómez-Pinilla [@CR525]; Hadacek et al. [@CR578]; Hayes [@CR612]; Hoffmann [@CR639]; Mattson [@CR1011], [@CR1012]; Radak et al. [@CR1228]; Rattan [@CR1254], [@CR1252]; Rattan and Demirovic [@CR1253]; Ristow and Zarse [@CR1282]; Sørensen et al. [@CR1415]), so any analysis should be a systems analysis. The simple fact that, for instance, iron chelators improve prospects in Alzheimer's implies that there is a background level of*natural* repair (otherwise chelators would only slow the neurodegeneration and not reverse it) and that is not necessarily apparent from measuring only net effects. Hence, the need for accurate systems biology models.

The very fact that multiple reactions typically lead to the creation (and destruction) of a given metabolite (such as the hydroxyl radical) means that to minimise its concentration it is best to modify many reactions simultaneously. This exceptionally important point from systems biology should underpin any scientific and therapeutic programs.

### Systems biology methods {#Sec35}

Systems biology methods are typically classified into 'forward' and inverse' (Fig. [14](#Fig14){ref-type="fig"}). For the purposes of this discussion, I shall concentrate on*metabolic* networks (in contrast to signalling networks they transfer both matter and information, Kell [@CR763]). Metabolic and other networks are 'graphs' in that they consist of entities ('nodes', such as metabolites) that interact with each other via 'edges' (enzymatic reactions). There may of course be other interactions such those that do not involve substrates or products but are mediated via molecules (effectors) that modify the rates of reactions. The distinction between forward and inverse models is based on whether one starts with the parameters or variables of the system. In metabolic networks, the parameters are typically the starting concentrations of substances present and the kinetic constants (*K*~m~,*K*~i~,*V*~max~, etc.) of the enzymes. The variables are typically the concentrations of metabolic intermediates, and the metabolic fluxes that change over time until a steady state (if such exists) is attained. It is important to note that only the parameters control the system. In*forward systems biology*, we thus seek to create a model of the network based on its parameters, and this is done in four phases, the first two of which are qualitative and the second quantitative (Herrgård et al. [@CR624]; Kell and Knowles [@CR775]; Thiele and Palsson [@CR1506]).

### Forward modelling {#Sec36}

The first qualitative stage is one in which are listed all the reactions that are known to occur in the system or organism of interest; in the modern era, and especially for metabolic networks, these reaction lists are often derived in part from genomic annotations (Arakawa et al. [@CR56]; Palsson [@CR1148]) with curation based on literature ('bibliomic') data (Duarte et al. [@CR383]; Thiele and Palsson [@CR1506]). A second stage, again qualitative, adds known effectors (e.g. those involved in forming feedback loops), while the third and fourth stages---essentially amounting to molecular enzymology---include the known kinetic rate equations and the values of their parameters. Armed with such information, it is then possible to provide stochastic and ordinary differential equation models of the entire metabolic network of interest. In some cases, it is possible to make simplifying assumptions that require minimal knowledge of the kinetic parameters of the system and allow one to generate a time series of the system variables (Smallbone et al. [@CR766]). An attractive feature of metabolism, for the purposes of modelling, is that, in contrast to signalling pathways, metabolism is subject to direct thermodynamic and (in particular) stoichiometric constraints (Palsson [@CR1148]). These constraints are extremely important in reducing the search space for the values of the kinetic parameters of the model, and indeed constrain significantly the states that the system*can* adopt (Kell [@CR763]; Palsson [@CR1148]).

The modelling community has access to many tools, which are interoperable because they can be exchanged using community standards (Kell [@CR767]) of which the most popular (Klipp et al.[@CR804]) is SBML, the Systems Biology Markup Language (Hucka et al. [@CR658]) (<http://www.sbml.org/>). Models are best made, and made available, in SBML. In addition, there is recognition that it is desirable to be clear about the*meaning* (semantics) of the elements in the model (Ananiadou et al. [@CR47]; Attwood et al. [@CR72]; Kell and Mendes [@CR776]), since SBML puts no constraints on the names given to entities, and we have pioneered (Herrgård et al. [@CR624]; Pettifer et al. [@CR1197]) the use of semantic annotation of all the entities, whether by reference to persistent databases or via database-independent means (e.g. the use of SMILES (Weininger [@CR1610]) and InChI (Coles et al. [@CR293]; Stein et al. [@CR1431]) strings for small molecules). This is consistent with the MIRIAM proposals for describing the contents of a model accurately (Le Novère et al. [@CR868]), and we have also used (Herrgård et al. [@CR624]) the Systems Biology Ontology (<http://www.ebi.ac.uk/sbo/>) and the Gene Ontology (<http://www.geneontology.org/>) as especially pertinent and useful ontologies. Tools also exist for creating such networks using CellDesigner (<http://www.celldesigner.org/>) and SBMLMerge (Schulz et al. [@CR868]) for merging submodels, including visualising them (via the Systems Biology Graphical Notation (Le Novère et al. [@CR869]) (<http://www.sbgn.org/>) e.g. via Arcadia (Villéger et al. [@CR1554]) (<http://www.sourceforge.net/projects/arcadiapathways/>). Armed with such networks, it is possible to analyse their dynamics and other properties using tools/ modelling environments such as COPASI (Hoops et al. [@CR641]) (<http://www.copasi.org/>) and to compare model and experimental data, conveniently stored using SBRML (Dada et al. [@CR332]). Models and attendant metadata are best stored directly in databases, such as that set down in the B-Net database model (see Li et al. [@CR910]; Mehrotra et al. [@CR1023]) as used in our yeast model (Herrgård et al. [@CR624]) (<http://www.comp-sys-bio.org/yeastnet>).

Interrogating the model {#Sec37}
-----------------------

### Sensitivity analysis {#Sec38}

Armed with a model, there are a number of important studies that are usefully performed. The first is the study of the contribution of individual steps to the control of the variables of interest. This is the domain of local and global sensitivity analysis (Saltelli et al. [@CR1306], [@CR1317]), to which we have made significant contributions (e.g. Lüdtke et al. [@CR951]; Sahle et al. [@CR1298]; Yue et al. [@CR1685], [@CR766], [@CR767]). Sensitivity analysis studies the quantitative contribution of individual steps to the overall control of a process. The 'local' version has been popularised in biochemistry as 'metabolic control analysis' (e.g. Fell [@CR421]; Heinrich and Schuster [@CR619]; Kell and Westerhoff [@CR778]), and, for instance COPASI (Hoops et al. [@CR641]) calculates the control or sensitivity coefficients directly from a model. The results of these kinds of analyses are represented by a rank order of the most important reactions or parameters, which provides an important starting point for the combinatorial analysis of these complex networks. Formalisms such as Metabolic Control Analysis also explain why the modulation of individual steps singly rarely has much of an effect on an overall pathway (see e.g. Pérez et al. [@CR1172], [@CR1173]), reviewed by Gems (Gems and Doonan [@CR495]), for a typical example.

### Combinatorial analysis of parameter sensitivity {#Sec39}

As indicated above, it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways---indeed evolution is thought to have selected for robustness to individual parameter changes (Bornholdt and Sneppen [@CR175]; Kitano [@CR803]; Lehár et al. [@CR887]; Morohashi et al. [@CR1066]; Stelling et al. [@CR1432]; Wagner [@CR1575])---combinations of parameter changes can and do have major effects. A straightforward corollary of this is that in order to cause or inhibit the progression of diseases---including inflammatory diseases such as asthma (Biswas and Rahman [@CR156]; Bowler [@CR178]; Bowler and Crapo [@CR179]; Boyer and Liu [@CR180]; Chodaczek et al. [@CR275]; Ciencewicki et al. [@CR285]; Comhair and Erzurum [@CR299]; Galli et al. [@CR480]; Greene [@CR558]; Han et al. [@CR589]; Horváth et al. [@CR645]; Jarvis et al. [@CR682]; Kocyigit et al. [@CR812]; Muñoz et al. [@CR1073]; Narula et al. [@CR1084]; Nemery [@CR1096]; Pae et al. [@CR1134]; Riedl and Nel [@CR1279]; Shore [@CR1386]; Vlašić et al. [@CR1569])---it is necessary to affect multiple steps simultaneously. The problem is to find which ones, and that is a combinatorial problem that scales poorly. It is exactly here where the ability to interrogate a suitable model of the pathway comes to the fore, since computations to determine which combinations of parameters to affect can be done enormously more rapidly than can 'wet' experiments. To be explicit, if manipulating (let us say knocking out) just three genes out of 1,000 is necessary to secure a desired effect (as is often the case) and the question is to choose which three, the answer involves recognizing that this is a combinatorial optimization problem involving ca 100 million combinations---a trivial number computationally given a model and an easy number (i.e. 3) to work with post hoc, but an implausible number to interrogate with present experimental methods. See (Park et al. [@CR1147], [@CR1148]) for a nice example of the approach.

At all events, the results of running a systems biology model in the forward direction are the time-varying concentrations of variables that result from the network topology and parameters of the system, and these can then be compared with measured variables to see how accurate the model is.

Of course it is typically the case (i) that the variables predicted by the model differ from those that one has measured, and (ii) one has only measurements of the variables and not the parameters anyway. Since it is the parameters that determine the system behaviour, it is then necessary to try and estimate or infer the parameters of the systems from measurements of the variables, the domain of inverse modelling (Liu and Wang [@CR929]; Mendes and Kell [@CR1026]) or system identification (Bongard and Lipson [@CR169]; Ljung [@CR930]).

### Inverse modelling {#Sec40}

Finding the sets of parameters that can reflect a set (or sets) of variables is a much harder problem. If there are just 20 parameters, each of which can take just 10 values, there are at once 10^20^ combinations, although there may be multiple combinations that give a reasonable solution (the problem or system is then said to be under-determined). At all events, finding these combinations requires methods that can effectively search these combinatorial search spaces to find good solutions (they are not provably optimal solutions as these kinds of problems are NP-hard, Garey and Johnson [@CR488]).

There are many kinds of approaches to attacking these kinds of combinatorial optimisation problems, and I give two examples. The first uses evolutionary methods to modify the search for these parameters, while the second is Bayesian in character.

Evolutionary computing methods (e.g. Bäck et al. [@CR82]; Goldberg [@CR520], [@CR521]) use ideas from Darwinian evolution to select and modify parameters to achieve a desired objective (or objectives---this is known as multi-objective optimisation, Handl et al. [@CR591]). In an evolutionary algorithm, one selects a population of models encoding a different candidate set of parameters, assesses their performance, rejects those that perform poorly and modifies the parameters of the better-performing models using methods akin to recombination and mutation to create a second generation population and so on. Finally, one finds a candidate set of solutions that perform well and can indeed interrogate these solutions to determine the parameters that differ most frequently in the selected solutions from those in the starting pathway. These kinds of methods are recognised as highly effective (Banga [@CR94]; Banga and Balsa-Canto [@CR95]), and they have proved so for both modelling (Dada and Mendes [@CR332]; Mendes and Kell [@CR1027]; Moles et al. [@CR1057]; Rodriguez-Fernandez et al. [@CR1279]) and other optimisation problems (e.g. Broadhurst et al. [@CR190]; Kell et al. [@CR768]; Knight et al. [@CR807]; O'Hagan et al. [@CR1117], [@CR1118]; Platt et al. [@CR1206]; Rowe et al. [@CR1306]). A related and novel approach that we have developed (Wilkinson et al. [@CR767]) (and see Brown et al. [@CR197]) also evolves estimates of parameters, but in a somewhat different way. Evolutionary computing methods are amenable to ('coarse-grained') parallelisation that allows them to run on many (hundreds or even thousands of) processors simultaneously, and we have used this approach with great effectiveness (Wedge and Kell [@CR1604]; Wedge et al. [@CR1593]). Overall, the result of this kind of approach is the effective determination of the multiple parameters that are required to explain the system variables.

A conceptually quite different approach, which may of course be expected to lead to the same result (and which in consequence strengthens further any conclusions from e.g. an evolutionary computing approach), is an approach based on Bayesian inference (Jayawardhana et al. [@CR686]; Liebermeister and Klipp [@CR914]; Vyshemirsky and Girolami [@CR1574]) and known as Markov Chain Monte Carlo or MCMC. In this approach (which we do not rehearse in detail as those details have recently been published by us, Jayawardhana et al. [@CR689]), we have knowledge of the variables of interest and sample candidate models that can explain those variables using various estimates of their parameters*from a distribution*. The MCMC algorithm then slowly builds up the likeliest values of the parameters and their possible distribution given the demonstrable uncertainty.

### Detecting the modes or sites of action of a toxin {#Sec41}

Clearly, if we have measurements of the variables of a system before and after the addition of a toxin, we can estimate the parameters in the two cases and see which have most plausibly changed by applying these inferencing methods to the two cases. This automatically gives the mode(s) or site(s) of action of the intervention, whether of a toxic inhibitor or by any other means. In other words these methods can detect the modes or sites of action of anything that causes a system to change its state. Taking the Bayesian approach (see also e.g. Nidhi et al. [@CR1100]; O'Hagan [@CR1117]; Vyshemirsky and Girolami [@CR1574]; Wilkinson [@CR1627]), in the work described above (Jayawardhana et al. [@CR689]) we 'calibrated' our approach using purely simulated data in which we knew exactly which parameters had been changed (and in which direction) and showed that we could detect this accurately. We then applied our approach to an experimental system of metabolic engineering in *Lactococcus lactis* (Hoefnagel et al. [@CR638]) where the investigators had manipulated the activity of a specific enzyme to achieve a desired metabolic effect. Our approach detected both the enzyme whose activity had been modified and suggested the site of another significant pleiotropic effect (these always occur, Featherstone and Broadie [@CR419]). Thus, the power of this general approach is that it is free of specific hypotheses and thus guides us to the hypotheses that can best explain the data. These are classic data mining methods (e.g. Breiman [@CR186]; Kell and King [@CR774]; Kell and Oliver [@CR777]; Wu et al. [@CR1649]) that allow us to discover mechanisms of action that are unknown and/or have not previously been contemplated. Note, however, that such methods need careful handling from a statistical point of view (e.g. Altman and Royston [@CR40]; Broadhurst and Kell [@CR192]; Hastie et al. [@CR602]; Ioannidis [@CR670], [@CR671]). A variety of other network inferencing methods also exist (e.g. Lorenz et al. [@CR941]; Managbanag et al. [@CR983]; Stolovitzky and Califano [@CR1450]; Stolovitzky et al. [@CR1439]).

Why most toxins will have multiple sites of action {#Sec42}
--------------------------------------------------

A variety of means are available for testing these mechanisms further, including the use of modulation of the expression of constituent parts of the proposed pathways by genetic means (e.g. Jones et al. [@CR712]), and in particular the use of appropriate iron chelators and antioxidants, alone or (preferably) in combination. The combinatorial aspect is important, since there are theoretical grounds, as well as abundant evidence, to the effect that several steps in a network must be modulated*simultaneously* to exhibit substantial effects (see e.g. Ágoston et al. [@CR15]; Ambesi-Impiombato and di Bernardo [@CR42]; Bender et al. [@CR134]; Borisy et al. [@CR174]; Csermely et al. [@CR323]; Dancey and Chen [@CR338]; Fan et al. [@CR410], [@CR409]; Haggarty et al. [@CR579]; Hopkins et al. [@CR639]; Kaelin [@CR719]; Keith et al. [@CR760]; Kostoff and Delafuente [@CR833]; Millan [@CR1040]; Perlstein et al. [@CR1187]; Sharom et al. [@CR1361]; Shiomi et al. [@CR1371]; Wermuth [@CR1618]) (Brötz-Oesterhelt and Brunner [@CR194]; Chong and Sullivan [@CR279]; Costanzo et al. [@CR309]; Gerber et al.[@CR497]; Goltsov et al. [@CR524]; Hegreness et al. [@CR618]; Huang et al. [@CR653]b; Jia et al. [@CR699]; Koufaki et al. [@CR836]; Kuhn et al. [@CR844]; Lee et al. [@CR879]; Lehár et al. [@CR890], [@CR887], [@CR888]; Li et al. [@CR904]; Liby et al. [@CR911]; Morphy and Rankovic [@CR1067]; Pachauri et al. [@CR1131]; Reznichenko et al. [@CR1272]; Sarkar and Li [@CR1328]; Sarkar et al. [@CR1317]; Sawyers [@CR1331]; Schrattenholz and Šoškić [@CR1348]; Silver et al. [@CR1380]; Silver [@CR1393]; Sporn et al. [@CR1432]; Stommel et al. [@CR1452]; Suchy et al. [@CR1446]; Ulrich-Merzenich et al. [@CR1523]; Watterson et al. [@CR1589]; Weinreb et al. [@CR1601]; Whitehurst et al. [@CR1625]; Wong et al. [@CR1643]; Yeh et al. [@CR1655], [@CR1668]; Ying et al. [@CR1672]; Zamin et al. [@CR1692]; Zhang [@CR1699]; Zhang et al. [@CR1688]; Zimmermann et al. [@CR1704]). The same holds true for biotechnology (Kell and Westerhoff [@CR778]), in which typically we seek to maximise fluxes (Park et al. [@CR1159], [@CR1148]). Of course some molecules---both nutrients/ natural products and pharmaceutical agents---can act as both antioxidants and iron chelators; these are likely to be especially useful in minimising the damage from toxicants of many kinds.

Concluding remarks {#Sec43}
==================

Science consists of both analysis and synthesis, and thus a substantial amount of Science involves finding regularities ('Laws') that can be extracted from observables, even when some of those observables or their presumed causes seem to have little in common (Kell and Oliver [@CR777]; Oldroyd [@CR1133]; Westerhoff and Kell [@CR1622]). Thus, there are many kinds of toxins that can cause death or injury, but it is not necessarily obvious what they share in terms of their modes of action. What I have therefore sought to do here is to bring together the evidence for the autocatalytic involvement of poorly liganded iron (leading, *inter alia*, to hydroxyl radical formation) in a considerable number of these. Certainly the exact molecular mechanisms, cascades and networks involved in each case depend on many other factors, and appropriate systems biology methods can tell us what they are, but I would argue that the extensive evidence for iron's involvement that I cite here and elsewhere (Kell [@CR766]) is very hard to ignore. Hence, the view that iron is the nexus.
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